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ABBREVIATIONS 
ADO:    Adenosine 
AMP:    Adenosine monophosphate 
ADP:    Adenosine diphosphate 
ATP:    Adenosine triphosphate  
Arg-1:   Arginase-1 
BM:    Bone marrow 
BM-MDSC:   Bone marrow generated myeloid derived suppressor cells 
BSA:    Bovine Serum Albumin 
BzATP:   2’,3’-(4-benzoil)-benzoic-ATP  
Ca2+:    Ion calcium  
C/EBP-b:   CAAT/enhancer binding protein-beta 
CD:    Cluster of Differentiation 
Da:    Dalton 
DC:    Dendritic cells 
Dig:    Digitonin 
DNA:    Deoxyribosenucleic acid 
cDNA:   Complementary-double stranded DNA 
dsDNA;   Double stranded DNA 
ELISA:   Enzyme linked immunoabsorbant assay 
FACS:   Flow cytometry 
GM-CSF:   Granulocyte macrophage colony stimulating factor 
HEK:    Human Embryonic Kidney 
IFN-???  Interferon beta 
IFN-γ:               Interferon gamma 
IL:    Interleukin 
iNOS:   Inducible nitric oxide synthase 
Iono:    Ionomycin 
LPS:    Lipopolysaccharide 
2-MeSATP:   2-metiltio-ATP 
MDSCs:   Myeloid derived suppressor cells 
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MHC:    Major Histocomptability complex 
NB:   Neuroblastoma 
NF-kB:   Nuclear factor kappa light chain enhancer of activated B cells 
NO:    Nitric oxide  
PCR:    Polymerase chain reaction 
RT-PCR:   Reverse transcriptase- polymerase chain reaction 
PBS:    Phosphate Buffered Saline 
PGE2:   Prostaglandin E2 
RNA:    Ribosenucleic acid 
ROS:    Reactive oxygen species  
SP:    Sulfinpyrazone 
STAT:   Signal Transducer and Activator of Transcription 
TCR:    T-cell receptor 
T eff:    T effector cell 
TLR:    Toll-like receptor 
Th1:    T helper cells (Type 1) 
Th2:    T helper cells (Type 2) 
Treg:    Regulatory T cell 
TNF-?:   Tumor necrosis factor-alfa  
UDP:    Uridin diphosphate 
UTP:    Uridin triphosphate  
WT:    Wildtype 
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INTRODUCTION 
TUMOR AND IMMUNE SYSTEM 
The first evidence of the power of the immune system to recognize and destroy 
cancer cells, dates back 1809 when William Coley found that injection of erysipelas 
directly into the tumor produced remission in some sarcoma patients [1]. 
This and other observations led nearly a century later, the development of the 
“Immunosorveillance theory” purposed by Brunet and Thomas. According to this 
theory the specific neo-antigens expressed by tumor cells would have induced an 
immune stimulation, leading the elimination of the malignancy [2]. In addition both 
researchers hypothesized that the higher organisms would have developed some 
mechanisms protecting them from tumors in allogenic rejection-like manner. 
Unfortunately discordant results obtained in the subsequent years, and increasing 
evidences of the inability of the immune system to effectively destroy the tumor, led 
the abandonment of the theory. Furthermore there was a growing conviction that the 
nature of the immune response in cancer is a complex comprised of highly 
orchestrated and integrated innate and adaptive responses, that reveal a delicate 
balance between positive and negative stimuli [3]. 
On the other hand the tumor develops escaping mechanisms able to induce a potent 
suppression of the immune response, acting at localized and systemic level. An 
important role in this phenomenon is played by the genetic instability of cancer cells, 
that affects antigens expression, components of the MHC or the IFN-? signaling 
pathway. 
Taken together these observations led a review of the Brunet and Thomas’ theory, 
introducing the “cancer immunoediting” hypothesis, that summarizes the complex 
relationship between the immune system and cancer cells in three main events: 
1) Elimination: in the beginning the immune system can recognize and destroy 
tumor cells. 
2) Equilibrium: the tumor growth arrests and the immune response selects and/or 
promotes tumor cell variants with increasing capacities to survive the immune 
attack. 
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3) Escaping: the survived tumor cell variants expand in an uncontrolled manner. In 
this phase the malignancy is clinically detectable.
Figure 1. Three phases of the “cancer immunoediting” 
Elimination, Equilibium and Escape. In the first and second phases tumor cells (blue) and 
tumor cell variants (red) are underlyed stroma cells (gray): immune cells limit the growth of 
the neoplasm. In the last phase, as result of the equilibrium process, the selected tumor cell 
variants (red) expand in an uncontrolled manner. Different lymphocyte populations are as 
marked.  
The tumor immune escape is mediated by different mechanisms dealing with 
structural and functional changes, both in tumor and stroma cells, leading finally to 
the inability of even activated effectors immune cells to reject the tumor. 
For example tumor cells can affect the differentiation of DCs, inhibiting their 
functionality. This causes a reduction in the number of APCs (antigen presenting 
cells), resulting in a deficiency in T cells stimulation. Gabrilovich ad colleague have 
also found that this inhibition in the DCs maturation is probably due to the constitutive 
activation of STAT3 and inactivation of NF-Kb (nuclear factor B), consequence of the 
exposure to vascular endothelial growth factor (VEGF), IL-6 and M-CSF [4]. 
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Moreover an intensive secretion of several factors, such as transforming growth 
factor (TGF)-?, interleukin (IL)-10, reactive oxygen and nitrogen species, 
prostaglandins [5] and IL-1? led a rapid recruitment in the tumor microenvironment of 
immunosuppressive cells of lymphoid and myeloid origin.  
The cellular populations with regulatory effect on the immune response are: 
regulatory T cells (Tregs) (CD4+, CD25+, FOXP3+, CD39+, CD73+) [6, 7], tumor-
associated M2 macrophages (TAMs) [8], N2 neutrophiles, regulatory/tolerogenic 
dendritic cells (DCs) [9] and myeloid-derived suppressor cells (MDSCs) [10,11,12].  
Most of these populations in physiological conditions play an important role in the 
maintenance of the immune system homeostasis, for example Tregs dysfunctions 
are associated to autoimmune diseases with at times fatal outcome. 
Unfortunately the tumor can use these same mechanisms to its advantage. In fact 
the accumulation of Tregs and MDSCs in tumor microenvironment is widely stated 
and there are evidences of an increased role of MDSCs in the tumor-escape 
phenomenon. 
MYELOID DERIVED SUPPRESSOR CELLS 
The term Myeloid Derived Suppressor Cells (MDSCs) was reported for the first time 
in a letter to the editor of the journal Cancer Research, signed by Gabrilovich and 
colleague in 2007 [13]. 
From that moment MDSCs has been used to define a cell population that 
accumulates under inflammatory conditions such as infections, chronic inflammation, 
autoimmune disease and cancer, with the peculiarity to exert a potent suppression of 
T cells response both in vitro and in vivo. 
Characteristic of these cells is the ability to change their mediators expression (e.g. 
iNOS and Arginase I (ARG1)) and their differentiation state in response to 
environmental influences. MDSCs are also distinguished by their partially 
undifferentiated (immature) state and by the high capacity to release cytokines, 
reactive oxygen and nitrogen species [14]. 
A low amount of MDSCs is detectable also in an non-inflamed state, present 
predominantly in the bone marrow where participate in the normal process of 
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myelopoiesis (controlled by a complex network of soluble factors including GM-CSF, 
G-CSF, M-CSF, SCF, FLT3 and IL-3) [15]. 
In mice, MDSCs are commonly identified for the co-expression of the cell surface 
markers CD11b and Gr-1 [16]. Moreover, due to their partial undifferentiated state, 
these cells express several different markers and recently some groups have divided 
mouse MDSCs in two major subsets, based on the expression of Ly6C and Ly6G.  
As result of this classification we have: 
- “monocytic” MDSCs (CD11b+Ly6G+Ly6Clow)  
- “granulocytic/ neutrophil-like” MDSCs (CD11b+Ly6G–Ly6Chigh) [17, 18] 
these two cell subsets even differ in their immunosuppressive mechanism [19].  
As regard human MDSCs the same two subpopulations have been observed: 
- Lin−HLA- DR−CD33+ or CD11b+CD14−CD15+ for “granulocytic” MDSCs 
- CD14+HLA-DRneg/lo or CD11b+CD14+HLADRneg/ lo for “monocytic” cells [11, 20, 
21]. 
MDSCs accumulation in cancer 
It is strongly stated that tumor milieu is an highly inflammatory environment, rich on 
nucleotides and inflammatory mediators [22].  
It has been reported that many of these factors could? stimulate the MDSCs 
recruitment and expansion [11, 12]. Interestingly, also in the absence of tumor cells, 
chronic inflammation has been shown to provide the conditions for MDSCs 
accumulation and stimulation [23]. Furthermore there are evidences that anti-
inflammatory conditions cause a significant reduction of frequencies and 
immunosuppressive functions of tumor-infiltrating MDSCs [24, 25, 26].  
The chronic inflammatory factors associated to the expansion of suppressor cells 
are: 
- cytokines: IL-1?, IL-4, IL-5, IL-6, IL- 10, IL-13, tumor necrosis factor (TNF)-?, and 
interferon (IFN)-?
- growth factors: VEGF, TGF-?, granulocyte/macrophage colony-stimulating factor 
(GM-CSF), granulocyte colony-stimulating factor (G-CSF), and macrophage 
colony-stimulating factor (M-CSF) 
- chemokines C-C motif ligand: (CCL) 2, CCL4, CCL5, C-X-C motif ligand (CXCL) 
1, CXCL8, and CXCL12 
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- cyclooxygenase-2 (COX-2) as well as prostaglandin E2 (PGE2) [20, 21, 24, 51].  
All these mediators exert their effects in combination and in dose-dependent manner. 
In physiological conditions GM-CSF drives myelopoiesis, whereas G-CSF and M-
CSF induce further differentiation of myeloid cells to granulocytes or macrophages 
respectively [27]. However in tumor lesions, all three growth factors have been 
shown to be overproduced [28, 29]. Tumor-derived GM-CSF has been recently 
reported to be one of the key factors involved in the generation of MDSCs in a dose-
dependent manner [30]. Low GM-CSF concentrations, without IL-4, induce a robust 
generation of MDSCs and immature DCs from bone marrow hematopoietic precursor 
cells in vitro, on the contrary high concentrations of the growth factor stimulates the 
development of neutrophiles and mature DCs. Furthermore, GM-CSF in combination 
with IL-6, IL-1?, PGE2, TNF-? or VEGF has been shown to mediate the in vitro
generation of highly suppressive MDSCs from CD33+ mononuclear cells isolated 
from the peripheral blood of healthy donors [31].  
MDSCs: Mechanisms of Suppression  
Due to their heterogeneous phenotype, MDSCs can contribute to the tumor 
progression in several ways including inhibition of both innate and adaptive immunity 
and induction of angiogenesis [32, 33]. 
At this regard some groups have found that the hypoxic conditions of the tumor 
microenvironment induce MMP and VEGF production by suppressor cells [34] 
regulated by the hypoxia inducible transcription factor HIF-1? [35]. 
The role of MDSCs in perturbing innate immunity is currently less defined, however 
observations suggest that MDSCs may suppress NK cells [36, 37] and polarize 
tissue macrophage differentiation toward a type 2/‘alternatively activated’ phenotype, 
(associated with tissue remodeling and pro-angiogenic activities) [38] thus enhancing 
tumor progression. It has also been suggested that MDSCs limit the availability of 
mature and functional DCs, which bridge the gap between innate and adaptive 
immunity.  
On the other hand the importance of the adoptive immunity suppression for cancer 
immune escape is well stated, therefore a robust investigation to elucidated how 
MDSCs inhibit T cells responses is now ongoing. Several studies have found that the 
T cells suppression requires cell-to-cell contact and can be antigen-specific or non-
specific. Moreover the mechanism is strongly associated to the involved MDSCs 
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subpopulation, suggesting a role for surface receptor interactions and/or short-lived 
soluble mediators.
MDSCs activation is reflected by an intensive NO production and ARG-1 expression, 
resulting in a strong inhibition of T cell reactivity [39, 40]. One of the major effects of 
MDSCs on T cell is the remarkable decrease in the TCR ?-chain expression, which 
plays a central role in coupling the TCR-mediated antigen recognition to various 
signaling pathways [41]. A profound down-regulation of TCR ?-chain expression has 
been detected in T lymphocytes infiltrating melanoma lesions from ret transgenic 
mice, in T cells from cancer patients [42, 43] and also from chronically inflamed mice, 
[44] suggesting a resemblance of both pathological processes. Moreover, a direct 
inhibition of TCR ?-chain expression has been observed upon an in vitro co-culture of 
MDSCs isolated from tumor-bearing mice or animals affected by chronic 
inflammatory conditions with normal T lymphocytes [45]. 
Factors involved in MDSCs immunosuppression 
Arginase (ARG1) 
The disruption of the metabolism of L-arginine, to affect the T cells functions has 
been extensively described in MDSCs [46]. 
The availability of arginine is a key factor for T-cells metabolism and it has been 
shown that the L-arginine depletion induces loss of CD3-? chain, blocks cell 
proliferation (being arrested in the G0-G1 phase of the cell cycle) and decreases 
cytokines production by lymphocytes in vitro.  
This important amino-acid is the substrate for two enzymes: iNOS (that generates 
NO) and arginase (ARG1) which converts L-arginine into urea and L-ornithine. 
MDSCs express high levels of both enzymes whose direct role in the inhibition of T-
cell function is well established [47].  
The expression of ARG1 is regulated by Th2 cytokines, especially IL-4 and IL-13. 
The increased activity of the enzyme in MDSCs enhances L-arginine catabolism, 
causing the depletion of this non-essential amino acid from the tumor 
microenvironment. This phenomenon has been described in patients with colon, 
breast, lung, and prostate cancer [48]. 
Usually the amino acids deprivation is an important mechanism for regulating of the 
lymphocyte response, in fact some data show that the CTLs suppression correlate 
even with the depletion of cysteine, phenylalanine and tryptophan [49, 50, 51]. 
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Tryptophan 
Tryptophan metabolism is increased in a tumor-conditioned microenvironment [54, 
52]. The enzyme involved in the metabolism of this amino-acid is the indoleamine 
2,3-dioxygenase (IDO), that catalyzes the degradation of the L-tryptophan to N-
formylkynurenine. It was interestingly shown that human monocyte-derived 
macrophages and in vitro-derived DC expressing IDO, inhibit T cell proliferation, 
[53,54] and has been suggested that the IDO expression by Myeloid Derived 
Suppressor Cells might protect tumor from T cells (inducing tolerance through 
tryptophan catabolism) [55]. 
Cysteine 
Cysteine is another amino-acid important for T cell proliferation and activation. 
Mammalian cells generate cysteine via two different pathways:  
- expression of plasma membrane cystine transporter xc: imports disulfide-bonded 
cystine from the oxidizing extracellular milieu to the intracellular reducing 
environment, where it can be reduced to cysteine [56, 57]  
- intracellular expression of cystathionase: it converts intracellular methionine to 
cysteine [58]  
Unfortunately T cells do not contain cystathionase or the xCT chain of the xc– 
transporter [59, 60], so they so can neither produce cysteine nor import cystine from 
the extracellular environment, making them dependent on other cells for production 
of the amino-acid (which is then imported through their ASC neutral amino acid 
plasma membrane transporter). 
Under physiological conditions DCs and macrophages, expressing both 
cystathionase and the xc–transporter, synthesize cysteine of which surplus is 
released and subsequently imported by T cells during antigen presentation. 
Interestingly MDSCs express the xc–plasma membrane transporter (permitting 
enhanced cystine uptake), but do not express neither cystathionase nor ASC neutral 
amino acid transporter (so are unable to import and export cysteine). Hence MDSCs 
are fully dependent on importing cystine from the extracellular environment, 
competing for, and depleting the necessary amino acid required for T cell activation 
and proliferation. This results in the inhibition of anti-tumor T cell responses [49]. 
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Reactive Oxygen and Nitrogen Species  
One of the major characteristics of MDSCs has been shown to be the high 
production of ROS. The up-regulation of this pathway, as well the molecular 
mechanism to which this underlies are strictly related to exposure of the cells at the 
tumor derived factors and the inflammatory mediators. Szuster-Ciesielska and 
colleagues have compared the ROS production by PMN isolated from the blood of 16 
patients affected by larynx carcinoma, with that of neutrophils obtained from 15 
healthy individuals. They have interestingly observed that the levels of ROS, 
especially spontaneous and PMA inducible superoxide, were substantially higher in 
cancer patients than in healthy volunteers. They also found that the rise was 
associated with the tumor stage. Moreover they have shown how, after partial or total 
laryngectomy, a significant decrease in ROS production and in the serum activity of 
catalase and peroxidase, occurred [61]. 
Several known tumor-derived factors, like TGF-?, IL-10, a number of other cytokines 
and growth factors released by tumor can induce ROS production, including IL-6, IL-
3, PDGF, GMCSF [62].  
It was even observed that ARG and iNOS can synergistically operate to inhibit 
antigen-specific T cell responses in vitro [63]. When both enzymes are induced at 
sufficient levels, under conditions of limited L-arginine availability, reactive nitrogen 
oxide species are produced by NOS2 [46]. 
Studies have shown that oxidative stress, caused by MDSCs, inhibited ?-chain 
expression in T cells and antigen-induced cell proliferation [64, 66, 67]. ROS are also 
known to trigger signaling related to angiogenesis.
Moreover both in vitro and in vivo, the inhibition of ROS production in MDSCs, 
completely abrogated the negative effect of these cells in mice and cancer patients 
[65]. 
Peroxynitrite 
Peroxynitrite (PNT), the product of interaction between NO and superoxide, is one of 
the most powerful oxidants. The main effect of the accumulation on PNT is the 
nitration of several amino acids such as cysteine, methionine, tryptophane and most 
prominently tyrosine. An increased concentration of PNT has been detected in 
inflammatory sites, characterized by accumulation of MDSCs or ongoing immune 
reactions. It has been shown that this phenomenon is directly implicated in the 
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promotion of tumor progression as it is documented for pancreatic cancer, malignant 
gliomas, head and neck cancer, breast cancer, melanoma and mesothelioma.  
It has been shown that the peroxynitrite production by MDSCs, during direct contact 
with T cells, resulted in nitration of the T-cell receptor (TCR) and CD8 molecules [68], 
leading conformational changes in the TCR-CD3 complex. This reduces the physical 
interaction between CD8 and TCR, abrogating the antigen-specific response. On the 
contrary, non-specific TCR-CD3 complexes remained relatively intact and the same 
T cells were able to respond to non-specific stimuli. These data suggest that the 
MDSC-induced defect, via releasing of peroxynitrites, is only specific to cells bearing 
TCR and involved in the interaction with the peptide presented by MDSCs. 
Interestingly the scavenger of PNT completely eliminated the MDSC-induced T cell 
tolerance, suggesting that ROS and peroxynitrite in particular, could be responsible 
for MDSCs mediated CD8+ T cell tolerance [69]. 
Other immunosuppressive mechanisms 
Several other mechanisms by which MDSCs lead tumor progression and immune 
escape have been identified: 
? Sakuishi and colleague have found that MDSCs express galactin 9, which binds 
TIM3 on lymphocytes and induces T cell apoptosis [70]. 
? MDSCs inhibit the homing to tumor draining lymph nodes of naïve T cells, 
reducing the activation of CD4+ and CD8+ cells. This effect is due to the ADAM17 
expression (disintegrin and metalloproteinase domain 17) that decreases the L-
selectin (CD62L) expression on the surface of naïve T cells, thus limiting T cell 
recirculation [71]. 
? MDSCs can also induce a tumor-promoting type 2 response. They lead this 
effect down-regulating IL-12 production by macrophages and increasing their 
production of IL-10 in response to signals from macrophages [72]. 
? MDSCs mediated immune suppression in ovarian carcinoma was suggested to 
involved a member of the B7 family of surface receptors (CD80) [73]. The up-
regulation of CD80 is critical for antigen presenting cells. Paradoxically, it was 
shown that this protein suppress T cells, when expressed by MDSCs. Moreover 
MDSCs from spleen and ascites of 1D8 ovarian carcinoma bearing mice, 
expressed high levels of CD80. The suppression was mediated by CD4+CD25+ T 
regulatory cells and required CD152. Other members of the B7 family inhibitory 
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molecules, like PD-L1 and PD-L2 receptors, are expressed on a variety of 
myeloid cells and were shown to be directly involved in the suppression of 
immune response [74]. 
MDSCs and T cells 
MDSCs and Treg 
In addition to MDSCs tumor harbors thymus-derived natural Treg and locally induced 
Treg (iTreg), both CD4+ CD25hi FoxP3+ immunosuppressive populations. Naive CD4+
CD25- can be converted into iTreg cells as a consequence of exposure to antigen, in 
the presence of TGF-? or IL-10 [75, 76]. There are increasing evidences that MDSCs 
are involved in the induction of iTreg and in the attraction and activation of Treg-cell 
subsets in general. Moreover it has been suggested that this mechanisms require 
cell-to-cell contact, including CD40–CD40L interactions [77], production of soluble 
factors such as IFN? and IL-10 [79], and expression of ARG [78]. 
Some in vivo studies have found that MDSCs support the development of Treg cells 
through TGF-?-dependent and –independent pathways [79]. Moreover it has been 
reported that the suppressive activity of Gr-1+CD11b+ MDSCs isolated from ovarian-
carcinoma bearing mice was dependent on the presence of CD80 on the MDSC and 
involved CD4+CD25+ Treg cells, suggesting a relationship between MDSC and Treg 
cells. 
In a B-cell lymphoma model, Serafini and colleague have identified MDSC as 
tollerogenic APCs, capable of antigen uptake and presentation to tumor-specific Treg 
cells. These CD11b+CD11clo MHCIIlo MDSCs expressed ARG-1 to mediate the 
expansion of Treg cells [79]. 
MDSCs and CD8+ Lymphocytes 
The suppressive role of MDSCs on CD8+ T cells is well established.?However the 
major unsolved question is if MDSCs mediate antigen-specific or non specific 
suppression of T cell responses. Recent findings suggest that both mechanisms 
actually occur and the discriminating factor seems to be the environment where the 
suppression takes place.  
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In the peripheral lymphoid organs the mechanism is antigen-specific and requires the 
presence of three factors: 
? MDSCs 
? activated antigen-specific CD8+ T cells  
? tumor-associated antigen.  
It was shown both in vitro and in vivo, that MDSCs inhibit IFN-? production by CD8+ T 
cells in response to peptide epitopes presented by MHC class I [80]. This antigen-
specific T cell tolerance is not operated by soluble factors, requires direct cell-to-cell 
contact and is probably mediated by reactive oxygen species [81, 82].  
Moreover MDSCs can uptake soluble antigens, including tumor associated antigens, 
to process and present them to T cells [83, 84]. Furthermore the blockade of MDSC–
T cell interactions with a MHC-class-I-specific antibody completely abrogated the 
MDSC-mediated inhibition of T cell responses in vitro [85]. 
Nagaraj and colleague have recently demonstrated that MDSCs caused CD8+ T cell 
tolerance only against the peptide they presented. In a system with CD8+ T cells 
expressing two different transgenic TCR on the same cells, MDSC did not affect the 
T-cell response against the peptide which was not presented by them [86]. 
The main subset of MDSCs responsible for CD8+ T cells tolerance is G-MDSCs, 
because of their prevalence in lymphoid organs of tumor bearing hosts and because 
of the nature of the immune suppression mediated by these cells. 
G-MDSCs in fact contain high levels of ROS and PNT, both instable molecules that 
can act only in short distance. The interface of MDSCs and CD8+T cells, interacting 
during the antigen-TCR recognition phase, provides the conditions of this 
suppressive event [60]. 
As regard the MDSCs suppressive activity at the tumor site, evidences suggest that 
the phenomenon is quite different and that could be antigen non-specific. When 
MDSCs migrate into the tumor, up-regulate the expression of ARG1 and iNOS, 
down-regulating the production of ROS and stimulating tumor-associated 
macrophages (TAMs) [87]. These MDSCs cells produce higher levels of NO and 
arginase compared to those detected in peripheral lymphoid organs of the same 
animals. Moreover TAMs produce several cytokines [88, 89] that suppress T-cell 
responses in a non-specific manner. 
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MDSCs and CD4+ Lymphocytes  
The main controversy about the suppressive activity of MDSCs, regards their role in 
CD4+ T cells suppression.  
Studies described different effects of MDSCs on T cells in cancer patients and tumor 
bearing mice and there are some evidences that although MDSCs induce antigen 
specific tolerance of CD8+, it does not occur for CD4+ T cells. However in different 
experimental systems, MDSCs induce inhibition of IFN-? production by CD4+ T cells 
[91]. 
An important thing to be considered in this argument is that in most of the 
experiments with MDSCs form patients’ peripheral blood, the specific nature of T cell 
suppression was not investigated. 
Recent studies have found that the antigen-specific CD4+ T cell tolerance in vivo was 
dependent on the expression of MHC class II by MDSCs [92]. 
The exact mechanism of MHC class II regulation in MDSCs is not clear, STAT3 may 
play a role because its up-regulation is a common finding in myeloid cells of tumor 
bearing hosts and it is known that it leads reduction of MHC class II expression in 
DCs [93, 94, 95]. Moreover many cytokines produced by the tumor may trigger 
STAT3 signaling in myeloid cells. 
Low expression of MHC class II (HLA-DR) was also reported in MDSC of patients 
with melanoma, leukemia and several solid tumors [97, 98]. 
On the contrary was also found that in tumor-bearing mice the antigen-specific CD4+
T cell suppression occurs only if MDSCs express a sufficient level of MHC class II. 
Moreover the antigen-specific CD4+ T cells, but not the CD8+ T cells, were able to 
convert MDSCs to non-specific suppressor cells both in vitro and in vivo (in a MHC 
class II dependent manner). The phenomenon was observed only in the presence of 
specific peptide and required direct cell-to-cell contact [92]. 
Gabrilovich and colleague have demonstrated that this effect involved MHC class II 
cross-linking, leading to up-regulation of COX-2 and PGE2, which were implicated in 
MDSCs mediated immune suppression [99].  
Prostaglandins E (PGE) are pro inflammatory modulators, secreted in the course of 
immune response by many types of myeloid cells. Autocrine production of PGEs is 
indirectly involved in the regulation of IL-12 production, depending IL-10 release [100]?
also implicated in the regulation of myeloid cell differentiation. The enzyme which 
underlies the production of PGE2 is cyclooxygenase-2 (COX-2) and there are 
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evidences of its expression in human lung, colon, breast and prostate cancers. 
Moreover in cancers with up-regulation of COX-2, prostanoids have been shown to 
induce arginase I expression, thereby contributing to tumor escape [47]. It is well 
stated that PGE2 induces MDSC differentiation and it is probably due to the 
interaction with E1 and E2 receptors. In fact EP2 receptor knockout mice show a 
delayed growth of 4T1 mammary carcinoma, associated to a lower number of 
MDSCs compared to relative wild type mice [101]. 
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ATP  
Adenosine thriphosphate is a key nucleotide involved in several important cell 
mechanisms.  
The intracellular role as energy source for the cells has been recognized for many 
years: cells have mechanisms for synthesizing, maintaining or rapidly restoring the 
intracellular level of ATP. In mammalian the ATP concentration in the intracellular 
compartment is 5-10 mM, but can reach much higher levels in specific intracellular 
stores, where the nucleotide concentration reach 100 mM.  
On the contrary, the extracellular ATP concentration in physiological conditions, is in 
the nanomolar range (50-20 nM). 
In case of plasma membrane damage such as in necrosis, cells leak their cytosolic 
content leading an immediate increase of the extracellular ATP concentration [102]. 
ATP can also be actively released by many different cell types, such as activated 
platelets [103], vascular endothelial cells [104], leukocytes and T lymphocytes [105].  
Figure 2. Structure of ATP 
ATP consists of adenosine, composed of an adenine ring and a ribose sugar, and three 
phosphate groups (triphosphate).
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The mechanisms of active ATP secretion by cells depends on the nature of the 
stimulus and/or the pathophysiological condition.  
The main ways to release the nucleotide in the extracellular microenvironment are: 
- opening of volume-sensitive channels [106]  
- purinergic X receptors (P2X)-gated channels  
- opening of connexin channels upon mechanical stress  
- release of the nuocleotide stored in cytoplasmic vesicles, such as in neurons and 
platelets [107]  
- pannexin (panx)-1 hemichannels, in response to increased cytosolic calcium 
concentration [108]  
The biological rationale of the release of ATP in extracellular microenvironment is the 
role of the nucleotide as extracellular messenger. 
This phenomenon was demonstrated for the first time in 1929 by Drury and Szent-
Gyorgyi who observed that extracellular ATP induces decrease of the strength and 
the velocity of cardiac muscle contraction. 
Moreover thirty years later was found that during antidromic stimulation of sensory 
nerves of the ear artery, the ATP was released in sufficient concentration to affect the 
muscular tone [109].  
Anyway the effective breakthrough came in 1972 when Geoffrey Burnstock 
demonstrated that ATP act as neurotransmitter, released by purinergic terminations 
in CNS neurons or in smooth muscle cells, and binds membrane receptors. 
Moreover Burnstock purposed the existence of two families of purinergic receptors, 
P1 and P2, capable to mediate effects of respectively adenosine and ATP. 
Functions of ATP as extracellular messenger 
When released in the extracellular milieu ATP mediates several different effects, 
depending on the nucleotide concentration and the nature of the cells involved in the 
phenomenon. 
Low concentration of nucleotide promotes proliferation of epithelial cells, fibroblasts 
and hematopoietic stem cells. This release also affects biological process such as 
platelet aggregation, neurotransmission, muscle contraction and cardiac function. 
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Low ATP concentration can affect several responses as pain sensation, cytokines 
secretion and NO production [110].  
Recent studies have also found that T cells, macrophages and microglial cells 
release ATP in extracellular environment after stimulation with different antigens or 
with LPS [111].  
Quite interestingly Lazarowski and colleague have shown that a notable release of 
the nucleotide can also occur without effective cell stimulation [112].  
Some studies have found that ATP have also chemotactic effect: tumor cells, 
attacked by T cells, release ATP form membrane lesions, leading the recruitment of 
phagocytic cells [113].  
Endothelial cells increase proliferation after stimulation with ATP. In these cells the 
effect is associated to a rise in the intracellular calcium concentration, diacil-glicerol 
and inositol 1-4-5 triphosphate production, MAP kynase activation, protein-kynase C?
traslocation and ERK kynase stimulation. 
In keratynocites, vascular smooth muscle cells [114], mesangial cells and astocytes, 
the observed proliferative effect of ATP depends on the activation of purinergic 
receptors P2Y. 
ATP and UTP act in vitro as potent growth factors for human hematopoietic stem 
cells, increasing the stimulatory effect of other growth factors [115]. 
The release of the nucleotide occurs also during the early stages of apoptosis, 
inducing monocyte/macrophages recruitment, acting as a “find me” signal to exert an 
efficient cell clearance [116].  
High concentrations of extracellular ATP are associated to inflammatory conditions, 
since the nucleotide is released by injured cells and by activated immune system 
cells [117].
CD39 and CD73  
Two important membrane-bound enzymes involved in the metabolism of extracellular 
nucleotides are CD39/(ENTPD1) and CD73/ecto-5’-nucleotidase. CD39 catalyzes the 
hydrolysis of ATP and ADP in adenosine–monophosphate (AMP), that is then 
converted in adenosine by CD73. 
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Interestingly CD39 and CD73 are simultaneously expressed in murine T regulatory 
lymphocytes (Tregs) and in a subset of human Tregs and monocyte-derived dendritic 
cells [118]. 
Deaglio et al. have shown that the adenosine produced by CD39/73-mediated 
cleavage of ATP, acts on T-effector cells resulting in cell cycle arrest [119]. Effects 
due to ATP catabolites rather than to ATP itself can be distinguished using non-
hydrolyzable ATP analogues (e.g. ATP-?-S), adenosine deaminase (ADA; that 
converts adenosine into inosine) or exogenous apyrases that hydrolyzes extracellular 
ATP. 
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PURINERGIC RECEPTORS 
Purinergic receptors are membrane receptors activated by extracellular nucleotides 
[120]. The family includes P1 receptors, activated by adenosine, and P2 receptors 
whose physiological agonist is ATP.?The intracellular signaling pathways activated by 
P2 receptors depend on the cell type, the pattern of receptors expressed and the 
nature of the stimulation. 
Two P2 receptor subfamilies have been described: P2X and P2Y [121].  
P2Y are seven membrane-spanning, G-protein-coupled receptors whose activation 
triggers calcium release from intracellular stores. Moreover effects of the activation 
depends on the G protein subtype involved. P2Y1, 2,4,6, and 11 are coupled to 
Gq/11 proteins that trigger the generation of inositol 1,4,5-trisphosphate and the 
release of Ca2+ from the intracellular stores. P2Y12, 13 and 14 are associated with 
Gi/0 proteins, which inhibit adenylate cyclases [122].  
P2X receptors are ligand-gated ion channels that modulate membrane permeability 
for monovalent and divalent cations [123].  
P2X receptors are constituted by two hydrophobic transmembran domains (TM1 and 
TM2), an extracellular region composed by 10 cysteins and cytoplasmic amino- and 
carboxyl- terminal domains.  
Upon activation P2X subunits aggregate to form homo- or in some cases hetero-
multimers and determine low molecular weight cation influx, plasma membrane 
depolarization and increase of intracellular Ca2+ concentration [124].  
Asapragin residues of P2X subunits are glicosilated and the deletion of al least two of 
them inhibits the formation of the channel.
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Figure 3. Structure of P2X receptor
In red is represented the transmembrane region 1 (TM1) and in blue the transmembrane 
region 2 (TM2). Are also highlighted the cysteine residues that form the disulfide bridges, the 
three sites of N-glycosylation (yellow) and the binding site with ATP.
Amino-terminal domain is constituted by twenty-thirty residues and is similar in all P2 
subtypes. On the contrary the carboxyl-terminal has a considerable variability in 
length. Mutations or deletions in the C-terminal domain affects kinetics, permeability 
and desentization of the ionic channel [125].  
The extracellular domain contains two disulfide-bonded loops (S-S) and three N-
linked glycosyl chains. Between Lys 69 and Lys 71 is localized the ATP binding site.  
The P2X subfamily is composed of seven members named P2X1-P2X7 [120].
P2X2, P2X4 and P2X7 receptors can make the transitions from channel to pore and 
have two opening states called I1 and I2 [126].  
The only known physiological agonist for P2X receptors is ATP, but this subfamily 
can also be activated by pharmacological analogues such as ??-metilene-ATP that 
unlike ATP, resists to enzymatic degradation. 
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P2X7 RECEPTOR 
Cloned in 1996 P2X7 receptor was included in the P2X subfamily because, under 
stimulation in physiological conditions, is selectively permeable to small cations. 
Moreover, in case of continued exposure to ATP, the cation channel can convert to a 
pore, permeable to small molecules as well as ions [127].  
In human the P2X7R gene includes 13 exons and is located on chromosome 12q24.  
Expressed by different cell types such as neurons, dendritic cells [128], macrophages 
[129], microglial cells[130], fibroblasts, lymphocytes [131] and endothelial cells the 
protein of P2X7 receptor can be over-expressed under stimulation with inflammatory 
mediators like INF-g, TNF-a and LPS. These observations suggest an involvement of 
the receptor in inflammatory response. Stimulation with high concentration of agonist 
or for prolonged period, have been shown to induce apoptosis [132]. 
P2X7 is also over-expressed by several malignant tumors [133, 134] and it has been 
shown to induce proliferative effect on T-cells [135]. Over the last years evidence has 
accumulated in support of an important role of P2X7 as an immunomodulatory 
receptor involved in IL-1? maturation and release, Ag presentation, graft-versus-host 
reaction and contact hypersensitivity [136].
The P2X7 receptor is a 595 aa protein structurally similar to other P2X receptors 
except for the fact that it has a significantly longer intracellular C-terminal (240 amino 
acids).  
P2X7R does not readily desensitize, therefore the pore remains open as long as the 
agonist is present in the extracellular environment. Although the molecular 
mechanism leading the pore formation is still unclear, in 1996 Surprenant and 
colleague have demonstrated the importance of the long C-terminal intracellular 
domain of which at least the last 177 amino acids are crucial for the induction of the 
non-selective pore [137].  
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?
Figure 4. P2X7 receptor stimulation 
In presence of ATP, P2X7R mediates Na+ e Ca2+ influx and K+ efflux through plasma 
membrane. Repeated stimulation with the agonist or higher concentrations of the same, 
result in the opening of a pore that allows the passage of molecules up to 900 Da.?
In human lymphocytes B and T the stimulation with ATP induces Na+ and Ca2+ flux 
throw plasma membrane and increases the permeability to ethidium bromide (314 
Da) [138]. Moreover in lymphocytes, the stimulation leads the formation of a smaller 
pore than in other cells, permeable to molecules of MW up to 320 Da. 
In peritoneal macrophages the P2X7 receptor makes multimerics complexes, on the 
contrary in glial cells and astrocytes the receptor was found only as a monomer 
[139]. 
Experiments of immunoprecipitation have shown that 11 proteins interact with the 
receptor. Two of them, RPTP? (receptor protein tyrosine phosphatase-beta) and HSP 
90, are able to modulate P2X7R funciotns [140]. 
Experiments with P2X7R truncated expressed in HEK293 and in Xenophus Laenis 
oocytes, have shown the importance of the C-term for the formation of the pore. On 
the contrary the channel functionality is not affected even if the receptor is truncated 
at 380 position. All these data suggest that unlike the pore, the channel formation 
requires only a short portion of the C-term [141]. 
P2X7 is an highly polymorphic protein and in last years four different aminoacid 
substitution that affect its functionality, have been identified. Both in human and in 
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mouse Glu 496 is important for the pore formation, in fact its substitution with an 
Alanine affects or, in case of homozygosity, completely abrogates the P2X7R 
functionality [142]. 
Moreover the substitution on an Isoleucyne with an Alanine in the C-term inhibits the 
membrane receptor expression [143], and the substitution of Glu 307 with an 
Arginine, abolishes the binding of the ATP to the extracellular domain. In our lab was 
identified in chronic lymphatic leukemia (CLL), the first polymorphism (His 155 –Tyr) 
that increases the receptor functionality [144]. 
The physiologic P2X7R agonist is ATP, in particular its tetra-anionic form (ATP4-). In 
physiological conditions ATP4- is associated to Mg2+, Ca2+ or H-, forming MgATP2-, 
CaATP2- and HATP3-. The removal of Mg2+ and Ca2+, or the alcalinization of the 
colture medium, increase the ATP affinity for the receptor [158]. The preferential 
agonist for P2X7 is 2’-3’-4(benzoil)-benzoic-ATP (BzATP), an pharmacological ATP 
analog with high affinity. Other, less effective than ATP P2X7 agonists, are 2-
MeSATP and ATP?S. 
?
29 
AIM OF THE WORK 
Although many therapies are currently available, cancer is still an unsolved problem. 
The main event supporting the growth of the malignancy is a well stated tumor-
induced tolerance. The major contributor to this phenomenon is a cell population 
identified in 2007 and defined Myeloid Derived Suppressor Cells. MDSCs 
accumulates under inflammatory conditions and induce a potent suppression of 
tumor immunity (innate and adaptative). Many laboratories are now working to 
understand the exact mechanism of the immunosuppressive activity of these cells, 
some models have been described and there are evidences that ROS and Arg-1 are 
involved but other molecules may probably play a role. Two of these additional 
agents might be extracellular ATP and adenosine. 
To explore the role of these factors in tumor-mediated immunosuppression I have 
carried out an extensive characterization of purinergic signaling in two MDSCs cell 
lines (MSC-1 and MSC-2) and in BM-MDSCs. Based on evidences that P2X7R 
supports the growth of several malignancies, my study was particularly focused on 
the expression and the functionality of this receptor. Moreover in the second part of 
the work I investigated the activity of two ecto-enzymes CD39 and CD73, responsible 
of the hydrolysis of ATP in adenosine.  
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MATERIAL AND METHODS 
MSC-1 and MSC-2 Cell Lines 
I worked on murine immortalized MDSCs cell lines: MSC-1 and MSC-2. Cells were 
originated by Prof. Bronte’s group in Padova as described in Apolloni et al. [151]. 
Briefly, the MSC-1 line originated from Gr-11 splenocytes from mice bearing a 1-
moold TS/A tumor, while the MSC-2 line originated from Gr-11 splenocytes from mice 
immunized 6 days earlier with a recombinant vaccinia virus encoding mouse IL-2. 
Both lines were immortalized with the insertion of the viral recombinant oncongenic 
sequences v-myc and v-raf.  
I cultured cells in RPMI 1640 (Euroclone, Milan, Italy) supplemented with 100 IU/ml 
penicillin, 50 ?g/ml streptomycin (all from Sigma-Aldrich, Milano, Italy) 1% L-
glutamine, 1% Sodium Pyruvate (Euroclone, Milan, Italy) and 10% fetal bovine serum 
superior (Biochrom, Cambridge, UK) at 37°C, in an a tmosphere of 5% CO2. 
Generation of BM-MDSC in vitro 
I isolated tibia and femur from C57black6 wild type and P2X7 KO mice, I flushed BM 
and I removed red blood cells with an ammonium chloride solution. 5x106 cells were 
cultured in 100 mm petri dish (Falcon, Beccton Dickinson) for 4 days with 40 ng/ml 
GM-CSF and 40 ng/ml IL-6 (both from Peprotech, London, UK) as suggested in 
Marigo and colleague’s work [149]. On day 4 some cells were stimulated with 300 ?M 
/ 1 mM ATP or adenosine. To confirm the differentiation in MDSCs at day 5 I 
assessed whether cells expressed surface antigens CD11b and Gr-1.  
I stained MDSCs for at least 20 min. at 4 °C with 1 :100 PerCp Cy5.5 anti CD11b and 
1:100 APC anti Ly6G (Gr-1). After two washes I acquired data with FACSCalibur (BD 
Biosciences, Mountain View, CA, U.S.A.) and analyzed them with the program 
FlowJo (Tree Star, Inc.). 
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Reverse transcriptase polymerase chain reaction 
I extracted total RNA using Trizol reagent (Invitrogen, Monza, Italy) following the 
manufacturer’s instructions. I carried out the reverse transcription reaction using the 
following specific primer sequences: 
The RNA samples (100 ng) were reversed transcribed using the ACCESS RT-PCR 
kit (Promega, Monza, Italy), with the following conditions: denaturation at 95°C for 2 
min (1 cycle) and reverse transcription at 48°C for  45 seconds (1 cycle); 33 cycles of 
denaturation at 94°C for 45 seconds, annealing at 5 6.5°C for 30 seconds, extension 
at 68°C for 1 min, followed by a final extension at  68°C for 4 min. As control I 
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evaluated Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) amplification, 
using the following primers: forward 5?-CAAGGAGTAAGAAACCCTGAC-3?; reverse 
3?-AATTGTGAGGGAGATGCTCAGT-5?. PCR products (100ng) were separated by 
agarose gel electrophoresis using an Agarose Electrophoresis Grade (Invitrogen) 
and then visualized by Gel Red staining. A 100-bp DNA Ladder (Fermentas, Thermo 
Scientific, Cornaredo, Italy) was used as a molecular weight. marker. PCR products 
were run on a 1.5% agarose gel containing 0.5 μg/ml ethidium bromide and 
photographed under UV light.  
Western blot analysis 
MSC-1 and MSC-2 cell lines were cultured in flasks and when 70% confluence was 
reached cells were detached with Cell Dissociation Solution (Gibco-Life 
Technologies, Monza, Italy) and centrifuged at 160 g for 5 min. The pellets were 
resuspended in sucrose saline containing benzamidine and PMSF and kept at -80°C. 
A 7.5% acrilamide gel was run by loading in each lane 30 μg of protein solubilized in 
O solution (10% w/v glycerol, 5% v/v 2-mercaptoethanol, 2.3% w/v SDS, 62.5 mM 
Tris-Cl, 0.003% bromophenol blue). Western blotting was performed by transferring 
proteins onto a nitrocellulose membrane (Amersham Biosciences, Little Chalfont, 
UK). Blocking of non-specific binding sites was achieved by incubating the 
membrane with 10% skim-milk in TBS buffer (10 mM Tris-Cl, 150 mM NaCl, pH 8.0) 
for 1 hour. The primary antibody was used overnight at respective dilution in TBS-t 
buffer. 
- anti mouse P2X7 (Sigma Aldrich, Milano, Italy): 1:200 in TBS-t + 2% BSA 
- anti mouse P2X3 (Alomone, Jerusalem, Israel): 1:400 in TBS-t 
- anti mouse P2X4 (Alomone, Jerusalem, Israel): 1:400 in TBS-t 
- anti mouse P2X5 (Alomone, Jerusalem, Israel) 1:400 in TBS-t 
- anti mouse CD39 (Abcam, Cambridge, UK) 1:500 in TBS-t 
- anti mouse CD73 (Abcam, Cambridge, UK) 1:500 in TBS-t 
- anti mouse ?-actin (Sigma Aldrich, Milano, Italy) 1:1000 in TBS-t  
Antibody binding was visualized by the protein A peroxidase-linked process (GE 
Healthcare, Milan, Italy). 
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Cytosolic Ca2+ concentration measurement 
Cells were loaded with the Ca2+ indicator fura-2/AM (2 μM) (Molecular Probes, 
Leiden, Netherlands) for 20 min at 37°C in a standa rd saline solution containing: 125 
mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM NaH2PO4, 20 mM HEPES, 5.5 mM 
glucose, 5 mM NaHCO3, 1 mM CaCl2 and 250 μM sulfinpyrazone (Sigma Aldrich, 
Milan, Italy), pH 7.4. Cells (1x106) were stimulated with BzATP (Sigma Aldrich, Milan, 
Italy) in a temperature-controlled magnetically stirred cuvette at 37°C and intracellular 
Ca2+ concentration ([Ca2+]i) changes were measured with a Perkin Elmer fluorometer 
(Perkin Elmer Ltd., Beaconsfield, United Kingdom). The excitation was at 340-380 
nm, and emission at 510 nm. Ca2+ concentration was calculated using the FLwinlab 
software (Perkin Elmer). 
Changes in plasma membrane permeability 
ATP and BzATP-dependent increases in plasma membrane permeability were 
measured by monitoring the uptake of the dye ethidium bromide (Sigma Aldrich, 
Milan, Italy). Briefly, 5 x 105 cells were resuspended in a Na+-free saline solution 
containing: 300 mM sucrose, 1 mM MgSO4, 1 mM K2HPO4, 5.5 mM glucose, 1 mM 
CaCl2 and 20 mM HEPES (pH 7.4 with KOH). Cells were kept in a magnetically 
stirred fluorometric cuvette, thermostatted at 37°C  and incubated in the presence of 
20 μM ethidium bromide (Sigma Aldrich, Milan, Italy). To achieve complete 
permeabilization of the cells, 100 μM digitonin was added at the end of the 
experiment (100% fluorescence signal). Fluorescence was measured at an 
excitation/emission wavelength couple of 360/580 nm. 
Lucifer yellow uptake assay 
ATP and BzATP-dependent increases in plasma membrane permeability were 
measured by monitoring the uptake of the fluorescent dye lucifer yellow (Molecular 
Probes, Inc.). 2 x 105 cells were seeded in 12-well pate in a standard saline solution 
containing: 125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM NaH2PO4, 20 mM HEPES, 
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5.5 mM glucose, 5 mM NaHCO3, 1 mM CaCl2 and 250 μM sulfinpyrazone (Sigma 
Aldrich, Milan, Italy), pH 7.4. Cell were then incubated for 30 minutes at 37 °C in the 
presence of 1 mg/ml lucifer yellow and 300 ?M BzATP or 1 mM ATP respectively. 
After stimulation and several washings to remove the extracellular dye, cells were 
analyzed with an inverted fluorescence microscope (Olympus IMT-2, Olympus 
Optical Co. Ltd., Tokyo, Japan) equipped with a 20X objective. Images were acquired 
both in phase-contrast and fluorescence with a NIKON DS-2MV digital sight camera. 
Plasma membrane potential measurement  
Changes in plasma membrane potential were measured with the fluorescent dye 
bis[1,3-diethylthiobarbiturate)trimethineoxonal (bisoxonol) (Molecular Probes, Leiden, 
The Netherlands), at the wavelength pair 540/580 nm, as previously described 
(Falzoni et al., 1995). Experiments were performed in a spectrofluorometer (model 
LS50, Perkin Elmer Ltd., Beaconsfield, UK) equipped with a thermostat-controlled 
(37°C) cuvette holder and magnetic stirrer. 
LDH assay 
Lactate dehydrogenase (LDH) activity was measured according to standard 
methods. Briefly, MSC-1 (1 x 105) and MSC-2 (5 x 105) were plated overnight in 24 
wells plates, rinsed and incubated in culture medium in the presence of increasing 
ATP (Roche Diagnostics, Monza, Italy) concentrations for 8 h. Supernatants were 
then collected, cleared by centrifugation (10 min at 149 x g) and added to a solution 
containing, 0.63 mM pyruvate, 11.3 mM NADH, 44.4 mM K2HPO4, 16.8 mM 
KH2PO4 (pH 7.5). Absorbance was measured in a spectrofluorometer (Ultrospec 
3000, Pharmacia Biotech, Milan, Italy) at a wavelength of 340 nm. Cells were also 
lysed with 0.1% Triton X-100 (JT Baker, Milan, Italy) and cleared by centrifugation. 
Absorbance of these samples was considered as 100% of lactic dehydrogenase 
release. 
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IL-1? secretion measurement 
MSC-1 (5 x 104) and MSC-2 (2 x 105) were seeded in a polylisinezed (Sigma 
Aldrich, Milan, Italy) 24-well plates. Cells were primed with 1μg/ml LPS (Sigma 
Aldrich, Milan, Italy) for 4 h at 37°C, 5% CO2, fol lowed by stimulation with 100 μM or 
300 μM BzATP for 30 minutes. After stimulation the whole medium (300 μl) was 
collected and centrifuged at 160 g for 5 minutes, to remove any detached cells, 
followed by transfer of the supernatant to a fresh tube. Supernatants were stored at -
80°C and assayed with Mouse IL-1 ?, Quantikine ELISA (RandD Systems, Abingdon, 
UK) 
TGF-?1 secretion measurement 
MSC-1 (5 x 104) and MSC-2 (2 x 105) were seeded in a polylisinezed (Sigma 
Aldrich, Milan, Italy) 24-well plates. Cells were primed with 1μg/ml LPS for 4 h at 
37°C, 5% CO2, followed by stimulation with 100μM or  300 μM BzATP for 30 minutes. 
BzATP stimulations were performed also without the priming with LPS. After 
stimulation the whole medium (300 μl) was collected and centrifuged at 160 g for 5 
minutes, to remove any detached cells, followed by transfer of the supernatant to a 
fresh tube. Supernatants were stored at -80°C and a ssayed with Mouse TGF-?1 
Quantikine ELISA (RandD Systems, Abingdon, UK). 
Intracellular ROS concentration measurement 
Intracellular ROS levels were measured using dichlorodihydro- fluorescein diacetate 
oxidation. Cells (6 x 105) were plated in petri dish (MSC-1) or 6-well plates (MSC-2) 
and primed with 1μg/ml LPS for 4 h at 37°C, 5% CO2,  followed by stimulation with 
100μM or 300 μM BzATP for 30 minutes. 4 h co-stimulation with BzATP and LPS 
were performed too. After stimulation cells were detached and incubated with 10 μM 
CM-H2 DCFDA (Invitrogen, San Diego, CA) for 30 min. at 37°C. Cells were then 
analyzed using a Tali Image Cytometer (Life Technologies, Monza, Italy) set at 458 
nm excitation with a 525/20 nm emission filter (green channel). MSC-1 and MSC-2 
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were also incubated with 500μM H2O2 (Sigma Aldrich, Milan, Italy) for 4 h at 37°C, 
absorbance of these samples was considered as 100%.
Measurement of extracellular ATP 
Extracellular ATP was measured in the culture supernatants with the 
luciferase/luciferin method. Briefly, MSC-1 and MSC-2 were plated in 96-well plates, 
supernatants were withdrawn and 100 ?l of ATP-stabilizing diluent buffer 
(sucrose/EDTA solution) was added to the culture wells. Luminescence was 
measured in a Victor2 Wallac Perkin Elmer luminometer (Perkin Elmer, Wellesley, 
MA, USA) equipped with an automatic dispenser of an Enliten rluciferase/luciferin 
solution (100 ?l) (Promega, Madison, USA). The level of the fluorescence detected 
was compared with a standard ATP curve created for every single experiment. 
Thin Layer Chromatography (TLC) 
Enzymatic modification of nucleotide and nucleoside substrates was evaluated 
utilizing [14C]ADP (PerkinElmer Life Sciences). 2 mCi/ml [14C]ADP was added to cell 
cultures; aliquots were removed and analyzed for the presence of [14C]ADP 
hydrolysis products by TLC samples were then applied to silica gel matrix thin layer 
chromatography plates (Sigma-Aldrich) and migrated until the solvent (6:3:1, 2-
propanol/ ammonium hydroxide/ distilled H2O) front reached 4 cm beyond the 
application site. Plates were dried and incubated in a storage phosphor screen 
cassette overnight, after which the screens were analyzed on a GE Storm 860 
Imager. 
Flow Cytometry Analysis 
Quantitative flow cytometric analyses were performed using standard procedures. 
Cells were collected and stained for at least 20 minutes at 4°C in a PBS + 5% FBS 
solution with the respective antibody: 
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- allophycocyanin (APC) anti mouse CD39 (1:100) 
- PerCp anti mouse CD4 (1:400) 
- allophycocyanin (APC) anti CD8 (1:400)  
After the stimulation and two washings, data acquisition was performed using 
FACSCalibur flow cytometer (BD Biosciences, Mountain View, CA, U.S.A.) and 
analyzed by using FlowJo (Tree Star, Inc.). 
CFSE assay 
A CFSE stock (5 mM in DMSO; Invitrogen, USA) was thawed and diluted in 
phosphate-buffered saline (PBS) to the 10 ?M working concentrations. Freshly 
isolated splenocytes from C57blasck6 mouse were resuspended in PBS (0.1% BSA) 
at 1×106 cells/ml and incubated with CFSE (final concentration: 10 ?M) for 10 min at 
37 °C. Reaction was stopped with the addiction of 2 0 ml of cold medium and 
incubation at 4 °C for 5 minutes. Cells were then w ashed twice and resuspended in 
culture medium at 2×106 cells/ml.  
CFSE labeled T cells were cultured in 96-well flat bottom plates (Nunc Roskilde, 
Denmark) at 2×104 cells/well in the presence of different MDSCs concentrations 
(ratio T cells: MDSC: 1:1, 1:2, 1:4, 1:8). Cell cultures were stimulated with CD3/CD28 
Dynabeads (Invitrogen, Carlsbad, CA). In a parallel experiment CFSE labeled T cells 
were cultured alone with and without stimulation. After 3 days, cells were harvested 
and stained with 1:400 anti-CD8 allophycocyanin and 1:400 anti-CD4 PerCP Abs for 
at least 20 min at 4°C. CFSE signal of gated lympho cytes was analyzed by flow 
cytometry. 
Microscopic analyses 
MSC-1 and MSC-2 were plated in 24 mm round coverslips. Slips were then placed in 
a thermostatted Leyden chamber (model TC-202A, Medical Systems Corp., 
Greenfield, WI, USA) on the stage of an inverted Nikon Eclipse TE300 microscope 
(Nikon, Tokyo, Japan) equipped with epifluorescence and a 100X objective (Physik 
Instrumente, GmbH & Co., Karlsruhe, Germany). The bright field or fluorescence 
38 
images were captured with a back-illuminated CCD camera (Pricenton Instruments, 
Tucson, AZ, USA) using the Metamorph software (Universal Imaging Corporation, 
Downingtown, PA, USA). 
Immunofluorescence analysis 
MSC-1 and MSC-2 were centrifuged on polylisine slides, and fixed in 2%
paraformaldehyde (pH 7.4). After washing with PBS, the slides were incubated with 
ammonium cloride 100 mM for 20 min at 4C°, permeabi lized with Triton X-100 (0.1% 
in PBS) for 8 min and blocked with BSA (2% in PBS). Cells were then incubated for 1 
anti-ARG-1 Ab. Binding of primary antibodies was detected with fluorescein goat anti-
rabbit IgG (Invitrogen). After rinsing, the slides were counterstained with DAPI 
(Vectashield mounting, Vector Laboratories, Peterborough, UK). Digital images were 
acquired using a Nikon E-1000 fluorescence microscope equipped with appropriate 
filter sets and the Genikon imaging system software (Nikon Instruments, Tokyo, 
Japan). 
Evaluation of extracellular ATP levels in neuroblastoma microenvironment 
Six-week-old female immunocompetent syngeneic A/J mice (n=5) were intravenously 
(i.v.) injected in the tail vein with pmeLUC-NXS2 cells (2x105 cells/mouse). 
Bioluminescence imaging (BLI) was performed evaluating the stably pmeLUC–
transfected NB cell, by highly sensitive, cooled CCD camera mounted in a light-tight 
specimen box (IVISTM; Xenogen) as previously described(Bianchi et al.). BLI was 
performed after 7, 12, 19 and 26 days after tumor cell inoculum. In some 
experiments, immunocompetent syngeneic A/J mice were i.v. co-injected with murine 
NB NXS2 cells trasfected with firefly luciferase gene (NXS2-LUC) [158] and Gr-1high 
or Gr-1low MDSCs (1:1; 2x105 cells/mouse). The animals were imaged 8, 14, 20, 26 
days after tumor cell inoculum by BLI. 
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RESULTS 
MSC-1 and MSC-2 express the mRNA and the protein of purinergic receptors 
To evaluate whether MSC-1 and MSC-2 cell lines expressed P2 receptors, total RNA 
was isolated and probed by RT-PCR with specific primers for all P2X and P2Y 
subtypes. Figure 5 A shows the expression of P2X3, P2X4, P2X5, P2X7, P2Y6, 
P2Y12 and P2Y13 in both cell lines. On the contrary the mRNA of P2X6 was 
detected only in MSC-2. 
Moreover, as shown in Figure 5 B, by Western Blot I verified the expression of the 
proteins of P2X3, P2X4, P2X5 and P2X7 receptors. Quite interestingly, the P2X7R 
protein was more expressed in MSC-2 than MSC-1 (Fig. 5 C). 
  
Figure 5. Identification of P2 receptors transcripts and proteins. 
Panel A shows the mRNA expression of different P2Rs subtypes. Comparison with a 100-bp 
nucleotide ladder was used to determine the approximate size of the various P2 PCR 
products, detected by ethidium bromide staining. Panel B shows the protein expression of 
P2Rs subtypes and panel C shows the P2X7R expression in MSC-1 and MSC-2. Equal 
amounts of protein (30 μg) were loaded in each lane and incubated with either primary 
antibody. Mouse microglial lysates (N9) served as a positive control.
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The stimulation of MSC-1 and MSC-2 with ATP increases [Ca2+]i 
I have studied the activity of P2Rs expressed by MSC-1 and MSC-2. At first I have 
measured the intracellular calcium response after stimulation with several ATP 
concentrations (0, 3, 10, 100, 300 μM and 1-3 mM), both in presence and in absence 
of extracellular Ca2+. P2Rs were fully functional as both cell lines (Fig. 6 A) showed a 
large [Ca2+]i increase in response to the stimulation. It is worth of notice that the rise 
was mainly due to the influx of the ion from the extracellular space, as it was almost 
entirely abrogated by chelation of extracellular Ca2+ (Fig. 6 B). The dose-dependence 
curves show that the most effective concentration of ATP for MSC-1 and MSC-2 was 
in the range of 1 mM (Fig. 6 C). Moreover in MSC-1 the dose-dependency curve is 
biphasic, witnessing the activation of at least two P2 receptor subtypes: one with 
higher affinity, responsible for the [Ca2+]i increase at lower agonist concentrations, 
and another with lower affinity, responsible for the response at higher agonist 
concentrations [145].  
Figure 6. Calcium response to the stimulation with ATP. 
Panel A shows the [Ca2+]i increase in MSC-1 and MSC-2. Panel B shows the [Ca2+]I
response after stimulation in absence of extracellular calcium. Panel C shows ATP dose 
dependency curves in both cell lines. 
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The stimulation with BzATP is most effective in MSC-2  
I have measured the intracellular calcium concentration also in response to the 
stimulation with BzATP, the preferential P2X7R agonist. As shown in Figure 7A, 
P2X7R was fully functional in both lines. Quite interestingly the [Ca2+]i rise was over 
10 times larger in MSC-2 than in MSC-1 and was mainly due to the influx of the ion 
from the extracellular space, as it was almost entirely abrogated by chelation of 
extracellular Ca2+ (Fig. 7B). Dose-dependency curves show that the most effective 
BzATP concentration for MSC-1 and MSC-2 was in the range of 300 μM (Fig. 7C). 
Also in this case the BzATP dose-dependency curve is biphasic for MSC-1 line, 
suggesting the activation of at least two P2 receptor subtypes with different affinity for 
the agonist.  
Figure 7. Calcium response to the stimulation with BzATP.  
Panel A shows [Ca2+]i increases in MSC-1 and MSC-2. Panel B shows [Ca2+]i response after 
stimulation in absence of extracellular calcium. Panel C shows BzATP dose dependency 
curves of both cell lines. 
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The stimulation of P2Y receptors with UTP induces a transient calcium 
response 
In both cell lines I have studied the activity of P2Y receptors in response to the 
stimulation with UTP. The activation of P2YRs induces calcium release from the 
intracellular stores, resulting in an increase of the [Ca2+]i. Figure 8A shows that in 
MSC-1 and MSC-2, in the presence of extracellular calcium, UTP induced a transient 
[Ca2+]i increase, typical P2Y response. Moreover both curves of Figure 8A show that 
the moderate amount of the ion released from the stores was quickly reported to 
physiological levels. As shown in Figure 8C (MSC-2), even in case of chelation of 
extracellular Ca2+ a weaker response was detectable. 
The most effective concentration of UTP was in the range of 100 μM for MSC-1 and 
1 mM for MSC-2 (Figure 8B). 
Figure 8. Calcium response to the stimulation with UTP. 
Panel A shows the calcium response in MSC-1 and MSC-2. Panel B shows UTP dose-
dependency curve in both cell lines and Panel C shows the [Ca2+]i increases after stimulation 
of MSC-2 in absence of extracellular calcium. 
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In MSC-2 cell line different P2 subtypes are functional 
In the presence of extracellular calcium I have stimulated MSC-2 line with different 
P2Rs subtypes agonists. Figure 9A and 9B show that the stimulation with UDP and 
2MetSATP induced a transient calcium response. On the contrary the stimulation 
with UDP-glucose and αβMetATP were not effective (Figure 9C and 9D). 
Figure 9. Calcium response in MSC-2. 
Panels A-D show [Ca2+]i response in MSC-2 after the stimulation with UDP (Panel A), 
2MetSATP (Panel B), UDP-glucose (Panel C) and αβMetATP (Panel D).
2 min
1mM
UDP
0
400
800
[C
a2
+ ]
i, 
nM
2 min
1mM
UDP- glucose
0
250
500
[C
a2
+ ]
i, 
nM
2 min
1mM
2MetSATP 
0
250
500
[C
a2
+ ]
i, 
nM
2 min
1mM
αβMetATP
0
250
500
[C
a2
+ ]
i, 
nM
A
C D
B
44 
The stimulation with ATP and BzATP induces ethidium bromide uptake in both 
cell lines 
The hallmark of P2X7R activation is an ATP-dependent permeabilization of the 
plasma membrane to large molecules including the fluorescent dyes lucifer yellow, 
YO-PRO and ethidium bromide [146]. 
As shown in Figure 10 (A, MSC-1 and B, MSC-2) the stimulation of both cell lines 
with 1 mM ATP triggered Et-Br uptake, 56 % +- 14 and for MSC-1 and 69 % +- 13 for 
MSC-2. The most effective concentration of the nucleotide was in the range of 1 mM. 
Figure 10. Ethidium Bromide uptake in MSC-1 and MSC-2 after stimulation with ATP.
Figure 10 shows the EtBr uptake and the ATP dose dependency curves for MSC-1 (Panel A) 
and MSC-2 (Panel B) cell lines. 
Based on these data I focused my attention on the activity of P2X7R, stimulating 
cells with BzATP. As shown in Figure 11 A and B, the agonist lead an uptake of 
ethidium bromide even higher than ATP. The P2X7-mediated effect was particularly 
evident in MSC-2 where the level of permeabilization reach 83%. 
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. 
Figure 11. Ethidium Bromide uptake in MSC-1 and MSC-2 after stimulation with BzATP.
Figure 11 shows the EtBr uptake and BzATP dose dependency in MSC-1 (Panel A) and 
MSC-2 (Panel B) cell lines. 
To further confirm the involvement of P2X7R in the permeabilization response, I 
performed the same experiment after a 2 hours pre-incubation of MSC-2 with 600 μM 
oATP, a potent irreversible P2X7R antagonist. As we can see in Figure 12, the 
inhibition of P2X7R completely abrogated the ethidium bromide uptake.  
Figure 12. The inhibition on P2X7R abrogates Et Br uptake in MSC-2.  
Figure 12 shows the tracers of MSC-2 cells pre-treated with oxo-ATP and stimulated with 
ATP and BzATP. 
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The pore associate to the P2X7R is permeable to lucifer yellow in both cell 
lines 
I have verified if in MSC-1 and MSC-2 the pore associated to the P2X7 receptor was 
also permeable to higher molecular weight molecules than ethidium bromide.  
I therefore performed the experiment with lucifer yellow (MW 457 Da) a fluorescent 
dye that in particular conditions, such as the opening of the P2X7R pore, enters the 
cell that becomes visible at the fluorescence microscope. 
I acquired images in both phase-contrast and fluorescence. To analyze the data I 
compared the stimulated conditions (1 mg/ml lucifer yellow and 1 mM ATP or 300 μM 
BzATP) with two negative controls: one in the absence of the stimulation (“lucifer 
yellow”), and another without both lucifer - yellow and nucleotide (“control”). 
Figure 13 and 14 show that: 
- In the “negative control” any fluorescence was observed. 
- In the “lucifer–yellow” condition, no significant permeabilization to the dye was 
detectable. 
- In the presence of both fluorescent dye and stimulus (1 mM ATP or 300 μM 
BzATP), MSC-1 and MSC-2 underwent permeabilization of the plasma 
membrane to lucifer yellow which was observable as fluorescence emission. 
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Figure 13. MSC-1 images in phase contrast and fluorescence.  
The first couple of images show the negative control of MSC-1. The second couple of images 
show the cells in the presence of 1mg/ml of lucifer yellow. The forth and the fifth couples of 
images represent cells stimulated with ATP or BzATP in the presence of 1mg/ml lucifer 
yellow.
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Figure 14. MSC-2 images in phase contrast and fluorescence.  
The first couple of images show the negative control of MSC-1. The second couple of images 
show the cells in the presence of 1mg/ml of lucifer yellow. The forth and the fifth couples of 
images represent cells stimulated with ATP or BzATP in the presence of 1mg/ml lucifer 
yellow. 
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The stimulation of MSC-2 with ATP or BzATP induces depolarization of the 
plasma membrane 
I verified if the stimulation of purinergic receptors and in particular P2X7, could affect 
the plasma membrane potential in MSC-2 cell line. To detect the phenomenon I 
labeled cells with bisoxonol, a fluorescent dye that binds the membrane 
phospholipids. In case of membrane depolarization an increased fluorescence 
emission of the bisoxonol occurs and is detectable by a spectro-fluorimeter. I 
normalized data to the depolarization induced by 20 mM KCl which completely 
depolarizes the membrane and I considered as a 100% response.  
The stimulation of MSC-2 with 1 mM ATP induced 100% depolarization of plasma 
membrane (Figure 15) and the dose dependency curve shows that the nucleotide 
lead the maximum effect even at the concentration of 300 μM. 
Figure 15. Plasma membrane depolarization induced by ATP.  
Panel A shows the trace of MSC-2 cell line stimulated with 1 mM ATP. Cells were also 
treated with 20 mM KCl in order to evaluate the 100 % response. Panel B shows the ATP-
dose dependence curve. 
A
0
50
100
0 30 100 300 1000 3000
[ATP], μM
%
 D
ep
ol
ar
iz
.
5 min
1 mM 
ATP
Fl
uo
re
sc
en
ce KClKCl
KCl KCl
B
50 
As shown in Figure 16 the depolarization was mainly due to the P2X7R activation, as 
even the stimulation with 300 μM BzATP induced a 100% response. The dose 
dependence curve shows that the agonist was completely effective even at the 
concentration of 100 μM. 
Figure 16. Plasma membrane depolarization induced by BzATP.  
Panel A shows the trace of MSC-2 cell line stimulated with 300 μM BzATP. Cells were also 
treated with 20 mM KCl in order to evaluate the 100 % response. Panel B shows the BzATP-
dose dependence curve. 
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The stimulation with ATP and BzATP induces cell swelling and blebbing in 
MSC-1 and MSC-2 cell lines 
It is well stated that the dramatic upsetting of intracellular ion homeostasis caused by 
prolonged opening of the P2X7R pore, activates a chain of events leading to cell 
swelling, plasma membrane blebbing, mitochondria uncoupling, failure of oxidative 
phosphorylation and eventual cell death. Observing cells by the inverted microscope 
Nikon Eclipse TE300 I have verified that the stimulation with ATP and BzATP 
induced cell swelling and blebbing in MSC-1 and MSC-2.  
As shown in Figure 17 the effect of 1 mM ATP was detectable even in the first 
minutes following the treatment. Cells underwent a continuative re-arrangement of 
the plasma membrane, followed by an intensive blebbing. 
It would be interesting to verify if this was only a transient or an irreversibile effect. 
Figure 17. Phase-contrast images (100 X) of stimulation with 1 mM ATP in Na+ Ca2+
buffer solution.  
Cells were stimulated for 20 minutes with the nucleotide in a thermosttated chamber. I 
acquired images at 0, 10 and 20 miunutes. Red arrows indicate the morphological changes 
underwent by cells.
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I also stimulated both cell lines with 300 μM BzATP. As shown in Figure 18 the effect 
of the agonist was comparable to the effect induced by the stimulation with ATP, 
suggesting the involvement of the P2X7 receptor in the phenomenon. 
Figure 18. Phase-contrast images (100 X) of stimulation with 300 μM BzATP in Na+ Ca2+
buffer solution.  
Cells were stimulated for 20 minutes with the agonist. Red arrows indicate the morphological 
changes underwent by cells. 
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In order to further evaluate the involvement of P2XRs, and in particular P2X7, I have 
stimulated MSC-2 in a Na+-0,5 mM EGTA buffer solution. As shown in Figure 19 the 
absence of the extracellular calcium does not affect the response to 1 mM ATP, 
suggesting the involvement of the PY subfamily. On the contrary in case of 
stimulation with BzATP in the same conditions, the blebbing response was partially 
abrogated, further highlighting the involvement of P2X7 receptor.  
Figure 19. Phase-contrast images (100 X) of stimulation of MSC-2 cell line in Na+ - 0,5 
mM EGTA buffer solution.  
Cells were stimulated for 20 minutes with ATP or BzATP in absence of extracellular calcium. 
Red arrows indicate the morphological changes, in particular blebbing, underwent by cells. 
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The stimulation of P2 receptors induces a moderate LDH release by MSC-1 and 
MSC-2 
It is generally agreed that prolonged openings of the P2X7R pore is inevitably 
coupled to cell death [146]. There are however notable exception as for example 
human neuroblastoma cells, that despite the expression of a fully functional P2X7R 
pore, do not die even after prolonged exposures to high ATP concentrations [147]. 
Based on the result obtained by the imaging experiment I wondered whether the 
stimulation of MSC-1 and MSC-2 with nucleotides could have induced cell necrosis. 
In order to investigate the phenomenon I measured the release of the cytoplasmic 
marker lactic dehydrogenase (LDH) after chronic stimulation with ATP and BzATP.  
As shown in Figure 20 although the prolonged exposure (eight hours) to 3 mM ATP 
induced morphological changes in MDSCs cell lines, a modest release of LDH was 
detected (Figure 21), evidence that the P2X7R pore opening was uncoupled from 
cytotoxicity. This data could explain why MDSCs can survive in highly inflammatory 
environment such as the tumor milieu. 
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Figure 20. Phase-contrast images of chronic stimulation of MSC-1 and MSC-2 with 
ATP. Cells were stimulated for 8 hours with several ATP concentrations, images (20 X 
objective) were acquired at the end of the incubation time (Panel A shows MSC-1, Panel B 
shows MSC-2).
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Figure 21. Chronic stimulation of MSC-1 and MSC-2 with ATP induces modest LDH 
release. 
Cells were incubated at 37° C for 8 h in the presence of increasing ATP concentrations. LDH 
activity is expressed as % of total activity related to the enzyme released by Triton X-100 
(Panel A shows MSC-1, Panel B shows MSC-2). 
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I have also measured the LDH release from MSC-1 cell line after chronic stimulation 
with BzATP. As shown in Figure 22 even the prolonged activation of P2X7R agonist 
did not lead cytotoxicity 
Figure 22. Phase-contrast images and LDH release from MSC-1 after chronic 
stimulation with BzATP.  
Cells were incubated at 37° C for 8 h in the presen ce of increasing BzATP concentrations. 
Phase-contras images(20 X objective) were acquired at the end of the incubation time (Panel 
A). LDH activity is expressed as % of total activity related to the enzyme released by Triton 
X-100 (Panel B). 
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The stimulation of P2X7R triggers IL-1? release in both cell lines
In myelomonocytic cells P2X7R is well known to be coupled to inflammasome 
activation and IL-1β release [152]. To check whether this is also the case for MSC-1 
and MSC-2 lines, these cells were primed with LPS for 4 h, followed by the usual 
BzATP challenge. As shown in Figure 23 A and B, P2X7R stimulation caused IL-1β
release, especially at the higher concentration of 300 μM. Cytokine release was 
minimal, albeit clearly detectable in MSC-1 and substantially larger in MSC-2. 
Figure 23. P2X7R-dependent IL-1β secretion from MSC-1 and MSC-2 lines.  
Cell lines were primed for 4 hours with 1μg/ml LPS and then stimulated for 30 minutes with 
BzATP. At the end of this incubation time, cell free supernatants were assayed for IL-1?
concentration with Mouse IL-1 beta Quantikine ELISA kit (RandD Systems, Abingdon, UK) 
(Panel A refers to MSC-1 and Panel B to MSC-2). 
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P2X7R stimulation induces the release of TGF-?1 in MSC-1 and MSC-2
P2X7R has been reported to support the release of TGF-β1 from astrocytes. I 
evaluated if the BzATP stimulation, with or without the LPS priming, could have 
induced the cytokine release in both cell lines. 
Figure 24 A and B show that the stimulation of P2X7R induced TGF-β1 secretion in 
both cell lines. It should be noted that the release level of this immunosuppressive 
agent was already elevated under basal conditions and the amount of the cytokine 
detected in the medium was significantly higher in MSC-1 than MSC-2. This data is 
supported by Bronte and colleagues’ observation by which MSC-1 cell line is 
constitutively suppressive. In the contrary the stimulation with IL-4 is required to 
induce the same effect in MSC-2. 
Figure 24. P2X7R-dependent TGF-β1 secretion from MSC-1 and MSC-2 lines.  
Cell lines were primed for 4 hours with 1 μg/ml LPS and stimulated for 30 minutes with 
BzATP Stimulations were performed also without the priming with LPS. At the end of the 
incubation time, cell free supernatants were assayed for TGF-?1 concentration with Mouse 
TGF-?1 Quantikine ELISA (RandD Systems, Abingdon, UK). Data refers to 5 x 105 cells 
(Panel A refers to MSC-1 and Panel B to MSC-2).  
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The stimulation of P2X7R increases the intracellular ROS concentration in both 
cell lines 
The ROS production is an important phenomenon related to the immune suppressive 
activity of MDSCs. P2X7R has been reported to support release of ROS from 
macrophage. By the measurement of the fluorescence level induced by the DCFDA, I 
observed that the stimulation with BzATP, even without the priming with LPS, 
increased the intracellular ROS concentration in both cell lines. The effect was 
particularly evident in MSC-2. 
Figure 25. Stimulation of P2X7R leads ROS production in MSC-1 and MSC-2 cell lines. 
Panel A (MSC-1) and panel B (MSC-2) show the percentage of reactive oxygen species 
(ROS) with the oxidation-sensitive dye Dichlorodihydrofluorescein diacetate (DCFDA) as 
described in Materials and Methods. Results are expressed as % of the highest [ROS] 
detected related to the stimulation with 500μM H2O2 (not shown). 
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The stimulation of P2X7R increases ARG-1 expression in both cell lines
In collaboration with Prof. Pistoia’s group (Laboratory of Oncology, Istituto Giannina 
Gaslini, Genoa) we have check whether the P2X7R stimulation could affect the 
expression of ARG-1 in MSC-1 and MSC-2 cell lines. As shown in Figure 26 A, in 
MSC-1 line the stimulation with BzATP, even without the priming with LPS, increased 
the expression of ARG-1. On the contrary in MSC-2 line (Figure 26 B), the 
stimulation of P2X7R triggered the same effect only after a 4h priming with LPS.  
Figure 26. Stimulation of P2X7R leads ROS production in MSC-1 and MSC-2 cell lines. 
Cells were primed with 1μg/ml LPS for 4 hours, followed by stimulation with 100 μM BzATP 
for 30 min. Panel A (MSC-1) and panel B (MSC-2) show the expression of ARG-1 detected 
as described in Materials and Methods. Results are expressed as the mean fluorescent 
intensity ± SD from at least three different experiments performed. 
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Extracellular ATP is detectable in neuroblastoma tumor microenvironment  
Some of the data of this thesis were used for a publications with the research group 
of Prof. Pistoia (Istituto Giannina Gaslini, Genova). In this work we investigated the 
MDSCs population that accumulates in Neuroblastoma and we found that P2X7R is 
involved in the modulation of the activity of these cells. Neuroblastoma (NB) is a 
malignant neoplasia originating from the sympathetic nervous system. About 50% of 
NB patients present metastatic disease at diagnosis and only one third of them 
survives at 5 years despite surgery, radiotherapy and aggressive chemotherapy 
followed by autologous hematopoietic rescue. 
A breakthrough in in vivo ATP studies has been the development of the pmeLUC 
probe. This probe can be transfected into reporter or tumor cells, that can be then 
inoculated into experimental animal models to monitor by BLI changes in the eATP 
concentration at inflammatory or tumor sites [159].  
In order to detect extracellular ATP in NB microenvironment, in collaboration with the 
group of Prof. Pistoia, the murine NB NXS2 cell line was stably transfected with the 
pmeLUC probe (NXS2-pmeLUC), and i.v. injected into immunocompetent syngeneic 
A/J mice. Bioluminescence imaging (BLI) analysis of mice disclosed a diffuse 
luminescence in the peritoneal cavity, associated with specific light-emitting spots in 
the kidneys, adrenal gland and ovaries, i.e. at sites of tumor metastasisis (Fig. 27 
Panel A). BLI was carried out for up to 26 d after tumor cell inoculum (days 12, 19 
and 26), showing an increased emission intensity as tumor progressed. At the 
different time points, some mice (three for each) were sacrificed, tumor masses 
excised and analyzed for luminescence emission. Direct BLI of the excised masses, 
consistently showed that light-emitting foci coincided with tumor masses (Fig. 27 
panel B). These results indicate that extracellular ATP was specifically detected 
within tumor masses in NB bearing mice in amounts that increased in parallel with 
tumor progression. 
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Figure 27. ATP detection in NB tumor microenvironment by pmeLUC probe. 
Immunocompetent A/J mice (n=4) were i.v. injected with pmeLUC-NXS2 cells (2x105
cells/mouse). Panel A shows the animals imaged by bioluminescence 12, 19 and 26 days 
after tumor cell inoculum. Panel B shows a representative animal subjected to post-mortem 
macroscopic analysis. A light-emitting metastasis localized in the abdominal cavity is 
indicated by red arrow. This is a representative experiment out of three performed.
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MSC-1 and MSC-2 cell lines release ATP in the extracellular microenvironment 
Based on the evidence that ATP accumulates in the tumor milieu, I wondered if 
MDSCs could release the nucleotide in the extracellular microenvironment.  
Figure 28 shows that both cell lines under basal conditions released ATP in the 
extracellular environment. The amount of ATP detected for MSC-2 was quite higher 
than for MSC-1. 
Figure 28. Concentration of ATP released by MSC-1 and MSC-2.  
Cells were plated overnight in a 96 well plate, at the moment of the analysis supernatants 
were collected. The [ATP] released was measured both in cells and supernatants with the 
luciferine-luciferase assay. The level of the fluorescence detected was compared with a 
standard ATP curve created for every single experiment. The low amount of ATP detected in 
the supernatant could be mainly due to the degradation of the nucleotide by environmental 
agents (temperature, pH…) but we could not exclude even the involvement of other agents 
such as ectonucleotidases. The data is the result of three experiments, 10 wells each. 
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MSC-2 cell line express the protein of CD39 
Based on the observation that both cell lines released ATP in the extracellular 
microenvironment and on the work of Ryzhov and colleague that hypothesized the 
involvement of the adenosine in the immunesuppressive activity of MDSC, I verified 
the expression of two ectonucleotidases in both cell lines [148].  
CD39 and CD73 are two important membrane-bound enzymes involved in the 
metabolism of extracellular nucleotides. CD39 catalyzes the hydrolysis of ATP and 
ADP in adenosine–monophosphate (AMP), that is then converted in adenosine by 
CD73. Deaglio and colleague have recently related the expression of both enzymes 
with the suppressive activity of Treg cells [7].  
As shown in Figure 29 the only enzyme detected was CD39, whose protein was 
expressed in MSC-2. 
Figure 29. Identification of the proteins of CD39 and CD73. 
Figure 29 shows the protein expression of CD39 and CD73 in MSC-1 and MSC-2. Equal 
amounts of protein (30 μg) were loaded in each lane and incubated with either primary 
antibody. Mouse microglial lysates (N9) served as a positive control. 
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In vitro generation of BM-MDSC 
During the second year of the PhD course I had the opportunity to spend a research 
period in Prof. Bronte’s group in Padova, where I learned how to in vitro differentiate 
murine bone marrow in MDSCs [149]. 
I collected BM form C57black6 wild type and P2X7 KO mice and I stimulated cells for 
4 days with 40 ng/ml GM-CFS and 40 ng/ml IL-6. To confirm the differentiation in 
MDSCs I analyzed the expression of both markers CD11b and Gr-1. The level of 
expression was comparable to the values suggested by Marigo and colleagues.  
Figure 30 shows that after the differentiation the percentage of MDSCs did not 
change from wild type and P2X7 KO mice, suggesting that P2X7R expression was 
not involved in the differentiation process. 
Figure 30. FACS Analysis of CD11b and Gr-1 expression in wild type and P2X7KO 
MDSC. 
I stained wild type and P2X7KO MDSC with 1:100 PerCP/Cy5.5 anti CD11b and 1:100 APC 
anti Gr-1, as reported in Materials and Methods. I acquired data with FACSCalibur (BD 
Biosciences, Mountain View, CA, U.S.A.) and analyzed them with the program FlowJo (Tree 
Star, Inc.).  
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MDSCs express the protein of PX3, P2X5, P2Y6 AND P2X7R 
By Western Blot I verified the expression of the proteins P2X3, P2X5, P2Y6 and 
P2X7 receptors in BM-MDSCs (Figure 30 A and B). Quite interestingly the protein of 
these P2Rs subtypes was detectable only after the differentiation of the BM in 
MDSCs. Moreover Figure 31 B shows that the P2X7R expression decreased in 
response to prolonged stimulation with ATP. This phenomenon could explain how 
MDSCs can survive even in highly inflammatory environments.
Figure 31. Identification of P2 receptors proteins in BM and MDSC. 
Panel A shows the protein expression of P2X3, P2X5 and P2Y6 receptors in MDSC. Panel B 
shows the P2X7R expression normalized to ?-Actin. Equal amounts of protein (30 μg) were 
loaded in each lane and incubated with either primary antibody. Murine microglial lysates 
(N9) or murine macrophages cell line (J774) served as a positive control. 
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MDSCs release ATP in the extracellular microenvironment 
With the luciferine lucifase assay I evaluated wether even BM-derived MDSCs could 
release ATP in the extracellular milieu. 
Figure 32 shows that under basal conditions both wild type and P2X7KO cells 
released ATP in the extracellular environment. The amount nucleotide releases by 
wild type MDSCs was quite higher than the concentration released by P2X7 KO 
cells.
Figure 32. Concentration of ATP released by wild type and P2X7 KO MDSCs.  
Cells were seeded in a 96 well plate and the [ATP] released was measured with the 
luciferine-luciferase assay. The level of the fluorescence detected was compared with a 
standard ATP curve created for every single experiment.  
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ATP and UTP have chemotactic effect on MDSC 
There are evidences that MDSCs can migrate in the tumor site where exert their 
suppressive activity. It is well stated that nucleotides have chemotactic effect on 
different cell types. With a trans-well plate, I investigated whether ATP and UTP 
could have induced the same effect on MDSC. Figure 33 shows that, even if ATP 
and UTP increased the mobility of MDSCs, a real chemotactic effect was detectable. 
Figure 33. Chemotactic effect of ATP and UTP on MDSC. 
After a 2h serum starvation, cells were seeded on the upper chamber of a trans-well plate. 
Each well was filled with the respective condition (0,1% BSA as negative control, 60% FBS 
as positive control, ATP, UTP). In order to discriminate the real chemotactic effect from the 
increased cell mobility due to the presence of nucleotides, I stimulated two wells with ATP 
and UTP in the upper chamber. After 3 hours from the stimulation the number of cells 
detected in the lower chamber was counted. Panel A shows the phase-contrast images of 
the lower chamber after the incubation time (20X). Panel B shows the number of cells 
counted. 
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MDSCs express the protein of CD39 and CD73  
By Western blot I verified the expression of CD39 and CD73 in BM-MDSCs. As 
shown in Figure 34, MDSCs express the protein of CD39 (ectonucleoside 
triphosphate diphosphohydrolase-1) and CD73 (ecto-5?-nucleotidase). 
Figure 34. Identification of the proteins of CD39 and CD73. 
Figure 34 shows the protein expression of CD39 and CD73 in MDSC. Equal amounts of 
protein (30 μg) were loaded in each lane and incubated with either primary antibody. MSC-2 
cell line served as a positive control for CD39 expression. 
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The stimulation with ATP or adenosine increases the expression of CD39 
I investigated whether the stimulation of MDSCs with 300 μM ATP or adenosine 
could affect the expression of CD39 in MDSCs. I stimulated cells for 2 or 24 hours 
and I evaluated the level of the protein by FACS. As shown in Figure 35 the 2 h 
stimulation with ATP and the 24 h stimulation with adenosine increased the 
expression of CD39.  
Figure 35. CD39 expression in MDSCs. 
I stimulated MDSC for 2 and 24 hours with 300 μM ATP or adenosine (ADO) respectively. I 
stained cells with 1:100 APC anti CD39, I acquired samples with FACSCalibur (BD 
Biosciences, Mountain View, CA, U.S.A.) and analyzed the data with the program FlowJo 
(Tree Star, Inc.). 
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MDSCs express functional CD39 and CD73 
A recently revealed immunesuppressive mechanism of MDSCs action is that by 
expressing CD73 (ecto-5?-nucleotidase) and converting AMP in adenosine. I 
hypothesized that MDSCs could even hydrolyze ATP/ADP into AMP, therefore by 
TLC assay I verified whether ecto-enzyme CD39 was functional in these cells. 
As shown in Figure 36 the ectonucleoside triphosphate diphosphohydrolase-1 
(CD39) was really functional and it hydrolyzed ADP in AMP. Moreover I verified that 
AMP was converted in adenosine and quite interestingly an high amount of inosine 
was detectable.  
The role of inosine in the immune system is still controversial, but several works 
relate the molecule to immunesuppressive events [150]. 
Based on the observation that the stimulation with ATP increased CD39 expression 
in MDSCs, I evaluated if it could even affect the nucleotidase activity of cells. Quite 
interestingly I found that after ATP pre-stimulation, adenosine and inosine became 
detectable earlier (after 10 minutes of incubation) than in the unstimulated cells.  
  
Figure 36. Hydrolysis of extracellular 14C-radiolabeled ADP to adenosine and inosine.  
Figure 36 shows the autoradiography of the products of the hydrolysis reactions that 
converts ADP in AMP, adenosine and inosine.  
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The stimulation of MDSCs with ATP or adenosine increases their 
immunosuppressive activity in vitro 
In order to test whether ATP and adenosine would be involved in the suppressive 
mechanism of MDSCs, I evaluated how the stimulation of cells with these agonists 
could affect their suppressive activity on T cells proliferation. 
I pre-stimulated MDSCs for 2 and 24 hours with 300 μM ATP or 300 μM adenosine 
respectively and I co-cultured them for 72 hours with CFSE-labeled splenocytes 
activated with Dynabeads. At the end of the incubation time I collected splenocytes 
and I measured the CFSE dilution in CD4+ and CD8+ cells. 
As shown in Figures 37 and 38 the stimulation of MDSCs with ATP or adenosine 
increased MDSCs suppressive activity on CD4+ and CD8+ cells. The effect was more 
evident in the ratios 1:4 and 1:8. 
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Figure 37. MDSCs–mediated immune suppression on CD4+ T cells. 
- Panel A shows CFSE-labeled splenocytes, gated on CD4+ lymphocytes, unstimulated 
(left plot) and stimulated (right plot) with Dynabeads. Stimulation induced cell 
proliferation, detectable as CFSE-dilution. 
- Panel B shows CFSE-labeled splenocytes, gated on CD4+ lymphocytes, stimulated with 
Dynabeads, with MDSC in different ratios. The most suppressive ratios are 1:1 and 1:2. 
- Panel C: Pre-stimulated MDSCs with 300 μM adenosine for 2 h (left plot) or 24 hours 
(right plot) add to the splenocytes stimulated with Dynabeads. Gate on CD4+
lymphocytes. Adenosine 2 h increased MDSCs suppressive activity in the ratio 1:4 (light 
green arrow) and 1:8 (dark green arrow). Adenosine 24 h increased MDSCs suppressive 
activity in the ratio 1:4 (light green arrow). 
- Panel C: Pre-stimulated MDSCs with 300 μM ATP for 2 h (left plot) or 24 hours (right 
plot) add to the splenocytes stimulated with Dynabeads. Gate on CD4+ lymphocytes. 
ATP 2 h increased MDSCs suppressive activity in the ratio 1:8 (dark green arrow). ATP 
24 h increased MDSCs’ suppressive activity in the ratio 1:4 (light green arrow). 
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Figure 38. MDSCs–mediated immune suppression on CD8+ T cells. 
- Panel A shows CFSE-labeled splenocytes, gated on CD8+ lymphocytes, unstimulated 
(left plot) and stimulated (right plot) with Dynabeads. Stimulation induced cell 
proliferation, detectable as CFSE-dilution. 
- Panel B shows CFSE-labeled splenocytes, gated on CD8+ lymphocytes, stimulated 
with Dynabeads, with MDSC in different ratios. The most suppressive ratios are 1:1 
and 1:2. 
- Panel C: Pre-stimulated MDSCs with 300 μM adenosine for 2 h (left plot) or 24 hours 
(right plot) add to the splenocytes stimulated with Dynabeads. Gate on CD8+
lymphocytes. Adenosine 2 h increased MDSCs suppressive activity in the ratio 1:4 
(light green arrow) and 1:8 (dark green arrow). Adenosine 24 h increased MDSCs 
suppressive activity in the ratio 1:4 (light green arrow). 
- Panel C: Pre-stimulated MDSCs with 300 μM ATP for 2 h (left plot) or 24 hours (right 
plot) add to the splenocytes stimulated with Dynabeads. Gate on CD8+ lymphocytes. 
ATP 2 h increased MDSCs suppressive activity in the ratio 1:8 (dark green arrow). 
ATP 24 h increased MDSCs’ suppressive activity in the ratio 1:4 (light green arrow). 
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Identification of Myeloid Derived Suppressor Cells from neuroblastoma-bearing 
mice 
In order to identify MDSCs subsets in the NB-bearing mice, in collaboration with Prof. 
Pistoia’s group, A/J mice were i.v. injected with the syngeneic murine NB NXS2 cell 
line. Single cell suspensions obtained from spleen, BM and PB were analyzed by 
flow cytometry. Control spleen, BM and PB were obtained from tumor-free (naïve) 
animals. We found that the percentage of CD11b+/Gr-1+ cells in the spleen (Figure 
39 A) and in the PB (Figure 39 B) of NB-bearing mice was significantly higher 
compared to naive mice.  
Figure 39. Accumulation of myeloid derived suppressor cells in neuroblastoma tumor-
bearing mice. 
Single cell suspension isolated from spleen, peripheral blood (PB) and bone marrow (BM) of 
naïve and NB tumor bearing mice (mice/group n=15) were stained with CD11b and anti-Gr-1 
antibodies and subjected to flow cytometry analysis.  
Panels A and B show the percentage of CD11b+/Gr-1+ cells in spleen and PB from naïve 
and tumor bearing mice. P values were calculated using Unpaired t test with Welch's 
correction. 
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Identification of Granulocytic and Monocytic Myeloid Derived Suppressor Cells 
subsets from neuroblastoma-bearing mice 
On the basis of the differential expression of Ly-6G and Ly-6C markers, a recent 
report identified two distinct subsets of MDSCs i.e. G-MDSCs and M-MDSCs from 
tumor bearing mice [30]. In order to investigate the presence of these MDSC 
subsets, splenic CD11b+ cells from NB-bearing and naïve mice were enriched in the 
G-MDSCs and M-MDSCs fractions by immunomagnetic sorting. We found that 
amount of G-MDSCs and M-MDSCs isolated from NB-bearing mice was significantly 
higher compared to that isolated from naïve mice (Figure 40). 
Figure 40. Accumulation of M-MDSC and G-MDSC in neuroblastoma tumor-bearing 
mice. 
Single cell suspension isolated from spleen, peripheral blood (PB) and bone marrow (BM) of 
naïve and NB tumor bearing mice (mice/group n=15) were stained with CD11b and anti-Gr-1 
antibodies and subjected to flow cytometry analysis.  
Figure 40 shows the percentage of MDSC-Gr high (G-MDSC) and MDSC-Grlow (M-MDSC) 
isolated from naïve and NB mice.
80 
P2X7R is expressed in Granulocytic and Monocytic Myeloid Derived 
Suppressor Cells subsets in neuroblastoma-bearing mice. 
In collaboration with Pistoia’s group we evaluated the P2X7R expression in MDSCs 
isolated from tumor bearing mice. Figure 41 A shows that both NB G-MDSCs and M-
MDSCs express P2X7R mRNA. Immunofluorescence analysis revealed a 
predominantly cytosolic, diffuse, staining in both MDSC subsets (Panel B). 
Interestingly however, NB M-MDSCs also showed a clear and specific patchy P2X7R 
fluorescence on the plasma membrane. No similar fluorescence pattern was ever 
detected in Naïve G-MDSCs and M-MDSCs, or from NB G-MDSCs. These results 
suggest an enhanced and specific plasma membrane localization of the P2X7R in M-
MDSCs. 
Figure 41. P2X7R expression in M-MDSCs and G-MDSCs in neuroblastoma bearing 
mice.  
Panel A shows the expression of murine P2X7 mRNA in M-MDSCs and G-MDSCs. RT-PCR 
was performed as described in Materials and Methods. GA3PDH amplification was used as 
positive control. Panel B shows P2X7 expression and localization in M-MDSCs and G-
MDSCs by fluorescence microscopy. Original magnification 40X, inset panels 100X. 
81 
P2X7 receptor is more functional in M-MDSCs 
One of the earliest changes occurring after P2X7R activation is the collapse of 
plasma membrane potential due to Na+ influx. As shown in Figure 42 A and B, the 
stimulation with BzATP caused a large plasma membrane depolarization in both 
MDSC subsets. Interestingly, P2X7R-dependent plasma membrane depolarization 
was larger in NB M-MDSCs than in Naïve M-MDSCs or G-MDSCs, whether from NB 
or naïve mice (Panel B). Changes in fluorescence were fully abrogated by the P2X7R 
blocker oATP (Panels A and B). Figure 42 C shows plasma membrane potential 
collapse of HEK293-P2X7 or HEH293-mock, used as positive and negative control, 
respectively.
Figure 42. P2X7R-associated plasma membrane permeability changes in M-MDSCs 
and G-MDSCs from neuroblastoma bearing mice.  
Panels A-C show BzATP-mediated induction of plasma membrane depolarization in Ca2+-
containing medium. Changes in plasma membrane potential were measured with bisoxonol 
as described in Materials and Methods.  
Panel A shows the tracers of Naïve G-MDSCs (black trace), NB G-MDSCs (orange trace), 
naïve G-MDSCs (red trace) and NB G-MDSCs (cyan trace) pre-treated with oxo-ATP.  
Panel B shows the traces of Naïve M-MDSCs (green trace), NB M-MDSCs (blue trace), 
Naïve M-MDSCs (red trace) and NB M-MDSCs (cyan trace) pre-treated with oxo-ATP.  
Panel C shows the traces of HEK293-P2X7 (red trace) and HEK293-Mock (black trace) cells 
used as positive and negative control respectively.
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Functional characterization of Granulocytic and Monocytic Myeloid Derived 
Suppressor Cells subsets from neuroblastoma-bearing mice 
Naïve and NB G-MDSCs and M-MDSCs subsets were then tested for ARG-1 
expression, ROS and TGF-β1 secretion. Figure 43 A shows that NB M-MDSCs 
expressed significantly higher levels of ARG-1 in comparison to naïve M-MDSCs 
(P=0.0001). In contrast, no ARG-1 expression was detected in naïve and NB G-
MDSCs. Figure 43 B shows that NB M-MDSCs and NB G-MDSCs had an enhanced 
ability to release ROS compared to naïve MDSCs. Furthermore in NB M-MDSCs 
produced a strikingly higher amount of ROS compared to NB G-MDSCs. As shown in 
Figure 43 C, no significant difference in TGF-β1 secretion was detected in NB and 
Naïve MDSCs, but in both animal models M-MDSCs secreted significantly higher 
amounts of TGF-β in comparison to G-MDSCs  
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Figure 43. Mechanisms of suppressive activity of M-MDSCs and G-MDSCs in 
neuroblastoma bearing mice.  
Panel A shows the percentage of ARG-1+ M-MDSCs and G-MDSCs. Data are expressed as 
mean value of ARG-1+ cells counted in 10 fields/slide. P values were calculated using 
Unpaired t test with Welch's correction. 
Panel B shows the level of reactive oxygen species (ROS) of M-MDSCs and G-MDSCs 
labelled with the oxidation-sensitive dye Dichlorodihydrofluorescein diacetate (DCFDA) as 
described in Materials & Methods. Results are expressed as the mean fluorescent intensity 
± SD from three different experiments performed. 
Panel C shows the level of TGF-β1 produced by M-MDSCs and G-MDSCs as assessed by 
ELISA. Conditioned media from triplicate cultures were tested in duplicate. Data are 
expressed as mean value ± SD. P value was calculated using Unpaired t test with Welch's 
correction.
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M-MDSCs are more tumorigenic than G-MDSCs 
In some experiments, we also tested whether NB M-MDSCs and NB G-MDSCs 
promoted in vivo tumor progression. As shown in Figure 44 A the size of tumors 
generated by co-inoculation of NB NXS2-LUC and NB M-MDSCs was significantly 
higher compared to tumors developed by co-injection of NB cells and NB G-MDSCs.  
Figure 44 B represents the size of tumors measured as BLI. 
Figure 44. Tumors size detected with BLI. 
Panel A shows four representative animals i.v. inoculated with NXS2 transfected with 
luciferase (NXS2-Luc) in combination with Gr-1high or Gr-1low MDSCs (1:1; 2x105
cells/mouse) and imaged by bioluminescence 26 days after tumor cell inoculum. Tumor 
volume is expressed as mean luminescence value ± SD. P value was calculated using 
Unpaired t test with Welch's correction (Panel B). 
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DISCUSSION 
The tumor induced-tolerance is a well established phenomenon that promotes tumor 
growth and expansion, resulting in the inability of the host immune system to 
effectively destroy the malignancy. 
Although in the last years many attempts to potentiate the immune response 
(immunotherapy) have been performed, most of them have not been effective.  
The first goal to shed light on this observation was the identification in 2007 of a new 
cell population, defined Myeloid Derived Suppressor Cells (MDSCs) [13], that 
accumulates in cancer and during bacterial or parasitic infections. Considered a 
major contributor to the failure of immunotherapies, MDSCs induce a potent 
suppression of tumor immunity (innate and adaptative). 
The accumulation and activation of these cells are driven by multiple factors secreted 
by the tumor, many of which detectable even during chronic inflammation. Several 
laboratories are now working to understand the exact mechanism of MDSCs 
immunosuppressive activity, groups have found that ROS [153] and Arg-1 [154] are 
involved but many other factors may probably play a role.  
Extracellular ATP is generally considered the prototypical danger signal, as it 
accumulates at inflammatory sites and within the tumor milieu at concentrations that 
may reach the hundred micromolar range. On the contrary, the nucleotide is almost 
undetectable in the interstitium of healthy tissues [155]. ATP is released into the 
tumor microenvironment by cancer cells and infiltrating inflammatory cells through 
different mechanisms including granule exocytosis, plasma membrane channels or 
lysis [22]. 
Moreover the nucleotide can be hydrolyzed in adenosine by CD39/(ENTPD1) and 
CD73/ecto-5’-nucleotidase, expressed in many different cell types included Tregs. In 
these cells the adenosine produced by CD39/73-mediated cleavage of ATP, acts on 
T effector cells resulting in cell cycle arrest [119]. Furthermore a recent work has 
shown the expression of functional CD73 in MDSCs, suggesting the involvement of 
the adenosine in their immunosuppressive activity [148]. 
Purinergic receptors (P2) are membrane receptors activated by extracellular ATP. 
Involved in many cellular functions such as vascular reactivity, apoptosis and 
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cytokine secretion, P2 receptors have been divided into two subclasses: P2X and 
P2Y [121]. 
P2Y are metabotropic receptors coupled to G proteins. Expressed in endothelial 
cells, dendritic cells, muscle, as well as neurons, monocytes, macrophages and B 
lymphocytes these receptors are activated by low concentrations of ATP. 
P2X receptors are ligand-gated ion channels whose activation leads the passage of 
ions through plasma membrane. Under physiological conditions P2X receptors 
activation results in Na+ and Ca2+ influx and K+ efflux across the cell membrane. 
In this subfamily is included P2X7 receptor, widely express in the body such as in 
immune cells [128], neurons and microglia [130]. Like all the P2XRs subfamily, under 
physiological stimulation P2X7R generates the selective channel for cations. On the 
contrary a sustained activation promotes the characteristic channel-to-pore transition 
leading the formation of a non-selective pore permeable to aqueous solutes of MW 
up to 900 Da. Furthermore P2X7R doesn’t undergo desensitization, therefore the 
pore remains open until the agonist is present in the extracellular environment, to 
close after the removal of the same. This latter event triggers cell death, via 
apoptosis or necrosis depending on the cell type and the given experimental 
conditions. Caspase and metalloproteinase activation are involved in this process 
[146] [132] [156]. 
P2X7R is over-expressed in several human malignancies including chronic B 
lymphocytic leukemia and NB, a pediatric tumor with grim prognosis in its metastatic 
presentation at diagnosis [133] [134] [157]. 
Based on all these observations I wondered if MDSCs expressed P2 receptors and 
what was the role of extracellular ATP and adenosine in the immunosuppressive 
activity. 
In two MDSCs cell lines, MSC-1 and MSC-2 [151] I have verified the mRNA 
expression of P2X3, P2X4, P2X5, P2X7, P2Y6, P2Y12 and P2Y13 receptors.  
In both cell lines is detectable the protein of P2X3R, P2X5R and P2X7R, that is 
highly expressed in MSC-2.  
The stimulation with ATP and BzATP induces a large [Ca2+]i response and the rise is 
over 10 times larger in MSC-2 than in MSC-1line. The [Ca2+]i increase is mainly due 
to the influx of the ion from the extracellular space, as it is almost entirely abrogated 
by chelation of extracellular Ca2+. In MSC-1 the BzATP dose-dependency curve is 
biphasic, witnessing the activation of at least two P2 receptor subtypes: one with 
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higher affinity responsible for the [Ca2+]i increase at low agonist concentrations, and 
another with lower affinity, probably P2Y receptors. In line with this hypothesis I have 
verified that the stimulation with UTP triggers a transient calcium response in both 
cell lines.  
P2X7R is fully functional as the stimulation with BzATP causes a massive uptake of 
EtBr and Lucifer yellow. It is worth of notice that also in this case MSC-2 line 
presents a larger response than MSC-1. 
Further evidence of the P2X7R functionality is the plasma membrane depolarization 
triggered by the stimulation of MSC-2 with ATP and BzATP. 
MDSCs accumulate in tumor microenvironment where they are likely exposed to high 
concentration of ATP. Quite interestingly I observed that although the P2X7R 
activation triggers swelling and blebbing, the phenomenon is uncoupled from 
cytotoxicity (modest amount of LDH release is detectable). This could explain how 
MDSCs can survive also in highly inflammatory environments. 
I have also verified that in basal conditions both cell lines release ATP in the 
extracellular space and the amount of nucleotide detectable is particularly elevated in 
MSC-2.  
As regard the immunosuppressive activity I have observed that the stimulation of 
P2X7R triggers the release of IL-1β, ROS and TGFβ and increases the expression of 
ARG-1. 
In the second part of the work I focused my attention on BM-MDSCs in witch I 
verified the protein expression of P2X3R, P2X5R, P2Y6R and P2X7R. As further 
evidence that P2X7R is uncoupled from citotoxicity, I observed that the chronic 
exposition of cells to high ATP concentration, leads a decreased expression of the 
receptor. 
Even BM-MDSCs release ATP in the extracellular space and P2X7R might play a 
role since the amount of nucleotide detected in wild type MDSCs is higher than in 
P2X7 KO cells. 
It is stated that suppressor cells originate in bone marrow and migrate into the tumor 
site where exert their activity. In order to further explain this phenomenon I 
interestingly observed that nucleotides, in particular ATP and UTP, have chemotactic 
effect on BM-MDSCs. 
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In 2011 Ryzhov and colleague found the expression of functional CD73/ecto-5’-
nucleotidase in MDSCs. They also hypothesizes the involvement of adenosine in the 
suppressive activity. 
In line with their hypothesis I verified that BM-MDSCs express both CD73/ecto-5’-
nucleotidase and CD39/(ENTPD1). Moreover I presented the first evidence that 
these cells can hydrolyze extracellular ADP in AMP, adenosine and quite surprisingly 
even an high amount of inosine is detectable. The role of inosine in inflammation is 
still controversial, but there are evidences that relate the molecule to 
immunosuppressive phenomena [150]. 
I furthermore observed that the stimulation of BM-MDSCs with ATP increases the 
protein expression of CD39 resulting an increased production of adenosine and 
inosine. 
The main question that this work aimed to response was if ATP and adenosine would 
have played a role in the immunosuppressive activity of MDSCs. 
At this regard I observed that the stimulation with 300 μM ATP or 300 μM adenosine 
increases the BM-MDSCs suppressive activity on the proliferation of CD4+ and CD8+
T effector cells.  
Further evidences of the involvement of ATP and P2X7R in the functionality of 
MDSCs are the results obtained in collaboration with Istutito Giannina Gaslini 
(Genova) in a murine model of Neuroblastoma (NB).  
A breakthrough in in vivo ATP studies has been the development of the pmeLUC 
probe that allows continuous monitoring of the extracellular ATP concentration in 
animal models for an extended length of time. Using this strategy, we have shown 
that levels of eATP increase with time in NXS2-pmeLUC NB tumors, thus paralleling 
tumor progression and metastasis dissemination. In agreement with a recent study 
showing the presence of CD11b+Gr-1+ MDSCs in the spleen, PB and BM of Neuro-2a 
NB bearing mice [160], we found that CD11b+Gr-1+ cells are enriched in the spleen 
and PB of NXS2 NB-bearing mice compared to naïve animals. Furthermore, NB M-
MDSCs expressed higher levels of ARG-1, and produced higher amounts of ROS 
and TGF-β1 in comparison to NB G-MDSCs. In addition we observed that the size of 
tumors generated by co-inoculation of NB cells and M-MDSCs was higher compared 
to that of control tumors (only NB cells) and tumors developed by co-injection of NB 
cells and G-MDSCs. Furthermore we found that although P2X7R was expressed to 
about the same level by M-MDCS and G-MDSC subsets isolated from the spleen of 
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NB bearing mice or naive animals, quite interestingly the subcellular location was 
different. In M-MDSCs from NB-bearing mice P2X7R was clearly expressed on the 
plasma membrane, while in G-MDSCs from tumor-bearing mice and in G-MDSCs 
and M-MDSCs from naïve animals it was mainly localized in the cytosol or in the 
nucleus. This sub-cellular location, in agreement with the results obtained with the in 
vitro stimulation, suggests that P2X7R may be more functional in NB MDSCs 
compared to the other Gr-1 subsets. Our study provides the first evidence that ATP 
modulates MDSCs responses via a P2X7R dependent mechanism. 
Based upon all the results, we propose a scenario whereby the extracellular ATP 
plays an important role in accumulation and functions of MDSCs.  
Suppressor cells express functional P2 receptors and both ecto-enzymes CD39/ 
CD73. The stimulation of P2X7R triggers release of immunosuppressive cytokines 
and quite interestingly is uncoupled from citotoxicity. Moreover this thesis presents 
the first evidence that in MDSCs the adenosine produced by CD39/73-mediated 
cleavage of ATP, acts on T effector cells resulting in cell cycle arrest. 
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